[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 714
1. Kudo M: Radiofrequency ablation for hepatocellular carcinoma: updated review in 2010. Oncology; 2010 Jul;78 Suppl 1:113-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiofrequency ablation for hepatocellular carcinoma: updated review in 2010.
  • Percutaneous radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC) was introduced in Japan in 1999.
  • On comparing outcomes between resection and RFA, they were comparable when cases were limited to those with 3 or fewer tumors 3 cm or smaller in many reports, based on which RFA has become the main treatment for small HCCs.
  • The 5-year survival rate following RFA was as high as 57% in patients registered in the Liver Cancer Study Group of Japan, 73% when cases were limited to liver damage A (Child-Pugh A), and 83.8 and 76.3% in liver damage A (Child-Pugh A) cases with a single 2-cm or smaller and 2- to 5-cm liver tumor, respectively, showing outcomes equivalent to those of resection.
  • The outcomes at our facility were also favorable: the 5-year survival rates of Child-Pugh A liver function HCC cases with 3 or fewer tumors 3 cm or smaller following RFA and resection were 84 and 78%, respectively.
  • TACE-combined, artificial pleural effusion- and ascites-combined, and contrast-enhanced ultrasonography-guided RFAs are good examples.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Catheter Ablation. Liver Neoplasms / surgery


2. Elgqvist J, Andersson H, Bäck T, Claesson I, Hultborn R, Jensen H, Johansson BR, Lindegren S, Olsson M, Palm S, Warnhammar E, Jacobsson L: Alpha-radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: Outcome related to measured tumor size and mean absorbed dose. J Nucl Med; 2006 Aug;47(8):1342-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alpha-radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: Outcome related to measured tumor size and mean absorbed dose.
  • (b) image the tumor growth on the peritoneum; and (c) calculate the specific energy and mean absorbed dose to tumors and critical organs.
  • At the time of treatment 29 animals were sacrificed and biopsies were taken for determination of tumor sizes using scanning electron microscopy (SEM).
  • Eight weeks after each treatment the animals were sacrificed and the presence of macro- and microscopic tumors and ascites was determined.
  • The specific energy and mean absorbed dose to tumors were calculated.
  • RESULTS: When given treatment 1, 3, 4, 5, or 7 wk after cell inoculation the tumor-free fraction (TFF) was 95%, 68%, 58%, 47%, 26%, and 100%, 80%, 20%, 20%, and 0% when treated with 211At-MX35 F(ab')2 or 211At-Rituximab F(ab')2, respectively.
  • The SEM images revealed maximum tumor radius of approximately 30 mum 1 wk after cell inoculation, increasing to approximately 340 mum at 7 wk.
  • Specific energy to cell nuclei varied between 0 and approximately 540 Gy, depending on assumptions regarding activity distribution and tumor size.
  • CONCLUSION: Treatment with 211At-MX35 F(ab')2 or 211At-Rituximab F(ab')2 resulted in a TFF of 95%-100% when the tumor radius was < or =30 microm.
  • The TFF was decreased (TFF < or = 20%) for 211At-Rituximab F(ab')2 when the tumor radius exceeded the range of the alpha-particles.
  • The specific antibody gave for these tumor sizes a significantly better TFF, explained by a high mean absorbed dose (>22 Gy) from the activity bound to the tumor surface and probably some contribution from penetrating activity.
  • [MeSH-minor] Alpha Particles. Animals. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / therapeutic use. Cell Line, Tumor. Female. Humans. Mice. Mice, Inbred BALB C. Mice, Nude. Microscopy, Electron. Neoplasm Transplantation. Rituximab. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Nucl Med. 2006 Aug;47(8):1238-40 [16882999.001]
  • (PMID = 16883015.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


3. Ozdegirmenci O, Kayikcioglu F, Haberal A, Ozfuttu A: Krukenberg tumor mimicking pregnancy luteoma. Gynecol Endocrinol; 2007;23(8):482-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Krukenberg tumor mimicking pregnancy luteoma.
  • BACKGROUND: Pregnancy-associated Krukenberg tumor is very rare, and the diagnosis in pregnancy is even more difficult.
  • The patient underwent exploratory laparotomy due to the onset of ascites and elevated tumor markers four months after delivery.
  • CONCLUSION: Krukenberg tumors should be considered in the differential diagnosis of pregnancy luteomas.
  • Otherwise, early diagnosis of the tumor can be delayed.
  • [MeSH-major] Krukenberg Tumor / diagnosis. Luteoma / diagnosis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Ascites / diagnosis. Diagnosis, Differential. Fatal Outcome. Female. Hirsutism / diagnosis. Humans. Pregnancy. Pregnancy Complications, Neoplastic. Young Adult

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17852427.001).
  • [ISSN] 1473-0766
  • [Journal-full-title] Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • [ISO-abbreviation] Gynecol. Endocrinol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


Advertisement
4. Wang Y, Juan LV, Ma X, Wang D, Ma H, Chang Y, Nie G, Jia L, Duan X, Liang XJ: Specific hemosiderin deposition in spleen induced by a low dose of cisplatin: altered iron metabolism and its implication as an acute hemosiderin formation model. Curr Drug Metab; 2010 Jul;11(6):507-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cisplatin is one of the commonly-used chemotherapeutic drugs to efficiently treat malignant tumors in clinic, however, the adverse effects of cisplatin such as nephrotoxicity, neurotoxicity, and hemolytic uremic syndrome are often observed at its clinical doses (approximately 60 mg/m(2)), which limit its broader application.
  • This paper reviews current understanding of cisplatin-induced erythrocyte injury, and presents our latest finding that a low dose of cisplatin (3.6 mg/m(2)/day, 14 days) could induce specific hemosiderin deposition in spleen of both normal and hepatoma-22 (H22) inoculated Balb/C mice.
  • This dose of cisplatin significantly inhibited H22-induced acute ascites development.
  • No significant toxicity was induced by this dose of cisplatin to tissues except for hemosiderin accumulation in the spleen of both normal and H22 tumor-bearing mice.
  • [MeSH-major] Cisplatin / administration & dosage. Disease Models, Animal. Hemosiderin / metabolism. Iron / metabolism. Liver Neoplasms, Experimental / metabolism. Spleen / metabolism
  • [MeSH-minor] Acute Disease. Animals. Carcinoma, Hepatocellular / metabolism. Carcinoma, Hepatocellular / pathology. Drug Administration Schedule. Humans. Mice. Mice, Inbred BALB C. Random Allocation. Tissue Distribution / drug effects. Tissue Distribution / physiology

  • MedlinePlus Health Information. consumer health - Iron.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Feb 17;403(6771):776-81 [10693807.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5909-16 [14522917.001]
  • [Cites] J Biol Chem. 2000 Jun 30;275(26):19906-12 [10747949.001]
  • [Cites] J Submicrosc Cytol Pathol. 2001 Jan-Apr;33(1-2):173-86 [11686400.001]
  • [Cites] Chest. 2001 Dec;120(6):2013-20 [11742936.001]
  • [Cites] J Biol Chem. 2002 Oct 18;277(42):39786-91 [12161425.001]
  • [Cites] J Vasc Surg. 2003 Jan;37(1):132-6 [12514590.001]
  • [Cites] Stroke. 2003 Jul;34(7):1693-8 [12805503.001]
  • [Cites] Blood. 2003 Aug 1;102(3):783-8 [12663437.001]
  • [Cites] Blood. 2003 Dec 1;102(12):4191-7 [12907459.001]
  • [Cites] Food Chem Toxicol. 2004 Sep;42(9):1469-77 [15234077.001]
  • [Cites] Hepatology. 1983 Mar-Apr;3(2):232-5 [6832714.001]
  • [Cites] Arch Esp Urol. 1985 Jan-Feb;38(1):28-34 [4039554.001]
  • [Cites] Annu Rev Biochem. 1987;56:289-315 [3304136.001]
  • [Cites] Electron Microsc Rev. 1992;5(2):209-29 [1581551.001]
  • [Cites] Chest. 1992 Dec;102(6):1794-9 [1446490.001]
  • [Cites] Mayo Clin Proc. 1993 Aug;68(8):757-62 [8331977.001]
  • [Cites] Tohoku J Exp Med. 1993 Jul;170(3):169-79 [8259589.001]
  • [Cites] Exp Mol Pathol. 1994 Oct;61(2):77-81 [7859830.001]
  • [Cites] Cancer. 1995 Apr 15;75(8):2083-8 [7697597.001]
  • [Cites] J Clin Invest. 1995 Apr;95(4):1650-9 [7706473.001]
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 1995 Sep;352(3):247-55 [8584039.001]
  • [Cites] J Exp Med. 1997 Feb 17;185(4):717-30 [9034150.001]
  • [Cites] Cancer Res. 1998 Jan 15;58(2):268-75 [9443404.001]
  • [Cites] Science. 2004 Dec 17;306(5704):2090-3 [15514116.001]
  • [Cites] Blood Cells Mol Dis. 2005 Jul-Aug;35(1):47-56 [15932798.001]
  • [Cites] Blood. 2006 Jan 1;107(1):341-8 [16141346.001]
  • [Cites] Crit Care Clin. 2006 Apr;22(2):347-55, viii [16678004.001]
  • [Cites] Biochem Pharmacol. 2006 Nov 30;72(11):1439-52 [16920072.001]
  • [Cites] Mini Rev Med Chem. 2007 Oct;7(10):1035-9 [17979806.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2008;48:495-535 [17937596.001]
  • [Cites] Toxicology. 2008 Mar 12;245(1-2):18-23 [18243469.001]
  • [Cites] Toxicology. 2008 Jul 10;249(1):40-4 [18499324.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Nov;62(6):977-84 [18274748.001]
  • [Cites] Mol Pharmacol. 2008 Oct;74(4):1132-40 [18635669.001]
  • [Cites] Kidney Int. 2008 Dec;74(12):1538-47 [18716605.001]
  • [Cites] J Histochem Cytochem. 2009 Jan;57(1):9-16 [18796409.001]
  • [Cites] J Korean Med Sci. 2008 Dec;23(6):1020-6 [19119447.001]
  • [Cites] Phys Med Biol. 2009 Mar 7;54(5):1209-21 [19182326.001]
  • [Cites] Arch Toxicol. 2009 Apr;83(4):341-9 [18754100.001]
  • [Cites] Exp Toxicol Pathol. 2009 May;61(3):223-42 [18986801.001]
  • [Cites] Cancer Chemother Pharmacol. 2010 Jan;65(2):373-82 [19763572.001]
  • [Cites] J Inorg Biochem. 2000 Apr;79(1-4):311-7 [10830882.001]
  • (PMID = 20540689.001).
  • [ISSN] 1875-5453
  • [Journal-full-title] Current drug metabolism
  • [ISO-abbreviation] Curr. Drug Metab.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z99 CA999999
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 9011-92-1 / Hemosiderin; E1UOL152H7 / Iron; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ NIHMS219653; NLM/ PMC2910113
  •  go-up   go-down


5. Manxhuka-Kerliu S, Petrusevska G, Maloku H, Sahatciu-Meka V, Loxha S, Loxha N, Shahini L: Hepatobiliary neuroendocrine carcinoma: a case report. J Med Case Rep; 2010;4:53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatobiliary neuroendocrine carcinoma: a case report.
  • INTRODUCTION: Neuroendocrine carcinoma of the gallbladder is a rather uncommon disease.
  • We report a case of a neuroendocrine tumor that was located in the wall of the gallbladder and that extended into the liver.
  • CASE PRESENTATION: A 52-year-old Caucasian woman presented with right-sided abdominal pain, ascites and jaundice.
  • An MRI scan revealed a tumor mass located in the gallbladder wall and involving the liver.
  • Histology revealed a neuroendocrine tumor, which showed scattered Grimelius positive cells and immuno-expressed epithelial and endocrine markers.
  • CONCLUSION: Gastroenteropancreatic neuroendocrine tumors need a multidisciplinary approach, involving immunohistochemistry and molecular-genetic techniques.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1989 Apr;13(4):292-302 [2648878.001]
  • [Cites] J Surg Oncol. 1980;13(3):215-22 [6990113.001]
  • [Cites] Pathology. 1993 Jan;25(1):90-4 [8316508.001]
  • [Cites] Am J Surg Pathol. 2001 May;25(5):595-601 [11342770.001]
  • [Cites] Med Sci Monit. 2001 Jul-Aug;7(4):746-50 [11433205.001]
  • [Cites] Acta Oncol. 2004;43(7):617-25 [15545182.001]
  • [Cites] Neuroendocrinology. 2006;84(3):155-7 [17312374.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2008 Apr;35(4):749-55 [18210106.001]
  • [Cites] World J Gastroenterol. 2008 Sep 21;14(35):5377-84 [18803349.001]
  • [Cites] Pathol Res Pract. 1991 May;187(4):472-6 [1652129.001]
  • [Cites] Semin Diagn Pathol. 1996 Nov;13(4):326-38 [8946610.001]
  • [Cites] Radiographics. 2002 Mar-Apr;22(2):387-413 [11896229.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2754-62 [15837990.001]
  • [Cites] Virchows Arch. 2006 Oct;449(4):395-401 [16967267.001]
  • (PMID = 20370888.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2836365
  •  go-up   go-down


6. Yang JH, Shi YF, Chen XD, Qi WJ: The influence of aquaporin-1 and microvessel density on ovarian carcinogenesis and ascites formation. Int J Gynecol Cancer; 2006 Jan-Feb;16 Suppl 1:400-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The influence of aquaporin-1 and microvessel density on ovarian carcinogenesis and ascites formation.
  • This study aimed at investigating aquaporin-1 (AQP1) distribution and expression in primary ovarian epithelial tumors, correlating with clinicopathologic variables and intratumoral microvessel density (IMD).
  • The AQP1 expression and IMD in 105 cases with primary epithelial ovarian tumors were measured by semiquantitative immunohistochemical technique.
  • AQP1 was located mainly in microvessels and small vessels but seldom in tumor cells.
  • Expression of AQP1 and IMD in ovarian malignant tumors was significantly higher than that in borderline tumors (P= 0.000, P= 0.001, respectively), and that in borderline tumors was higher than in benign tumors (P= 0.008, P= 0.028, respectively).
  • The expression of AQP1 in FIGO stage III-IV was more than that in stage I-II (P= 0.001), and cases with ascites volume greater than 1000 mL were more than cases with ascites volume less than 1000 mL (P= 0.000).
  • There is a positively correlated relationship between expression of AQP1 and IMD (correlation coefficient 0.60, P= 0.000) and between expression of AQP1 and ascites volume (correlation coefficient 0.57, P= 0.000).
  • These data implicate that high AQP1 expression may play an important role in the ovarian carcinogenesis, progression, and ascites formation.
  • Further studies into the mechanism of AQP1 regulation and the relationship between AQP1 expression and tumor angiogenesis may lead to novel therapies for ovarian carcinoma.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Ascites / etiology. Female. Humans. Microcirculation / physiopathology. Middle Aged

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515633.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 146410-94-8 / Aquaporin 1
  •  go-up   go-down


7. Hanna AM, Pham TH, Askegard-Giesmann JR, Grams JM, Iqbal CW, Stavlo P, Moir CR: Outcome of adrenocortical tumors in children. J Pediatr Surg; 2008 May;43(5):843-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of adrenocortical tumors in children.
  • PURPOSE: This study reviews adrenocortical tumors in children to determine factors that significantly affect outcome.
  • METHODS: An institutional review board-approved retrospective review from 1976 to 2005 identified 23 patients younger than 19 years old with histologic confirmation of adrenocortical carcinoma (ACC) and adenomas.
  • RESULTS: The mean age of the 23 children was 9.0 +/- 1.6 years; girls predominated (female-to-male ratio = 1.9:1) as did cancers (ACC 16, adenoma 7); tumor hormone production (74%); and advanced stage for disease (66%).
  • There was no perioperative mortality; morbidity was 10% (pneumothorax, acute renal failure, chylous ascites, and thrombocytosis).
  • CONCLUSIONS: Children, especially females with ACC present with large advanced-staged tumors.
  • The high percentage of children with functioning tumors suggests earlier detection is possible.
  • [MeSH-major] Adenoma / mortality. Adenoma / surgery. Adrenal Cortex Neoplasms / mortality. Adrenal Cortex Neoplasms / surgery. Adrenocortical Carcinoma / mortality. Adrenocortical Carcinoma / surgery

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18485950.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Majumder S, Chatterjee S, Pal S, Biswas J, Efferth T, Choudhuri SK: The role of copper in drug-resistant murine and human tumors. Biometals; 2009 Apr;22(2):377-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of copper in drug-resistant murine and human tumors.
  • In the present investigation, we addressed the question whether metal copper might be involved in drug resistance of murine and human tumors.
  • We found that the blood serum of tumor-bearing mice contained higher amounts of copper than healthy mice with tumors.
  • Secondly, mice bearing doxorubicin-resistant Ehrlich ascites carcinoma- or cyclophosphamide-resistant Lewis lung carcinoma contained more copper in their serum than mice bearing the corresponding drug-sensitive parental tumors.
  • Furthermore, the analysis of patients with breast cancer, colon carcinoma or lung cancer showed that the serum copper contents were higher in patients not responding to chemotherapy when compared to patients whose tumors responded to treatment.
  • [MeSH-minor] Adult. Aged. Animals. Cell Line, Tumor. Drug Resistance, Multiple. Female. Humans. Male. Mice. Mice, Inbred C57BL. Middle Aged. Neoplasm Transplantation

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. COPPER, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18956143.001).
  • [ISSN] 1572-8773
  • [Journal-full-title] Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine
  • [ISO-abbreviation] Biometals
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 789U1901C5 / Copper
  •  go-up   go-down


9. Ikeda K, Tate G, Suzuki T, Mitsuya T: Cytomorphologic features of immature ovarian teratoma in peritoneal effusion: a case report. Diagn Cytopathol; 2005 Jul;33(1):39-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immature embryonal and neuroectodermal components of such tumors are rarely observed in the ascites; to our knowledge, there have been only three reports of cytologic findings of immature teratoma cells in the ascites.

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2005 Wiley-Liss, Inc
  • (PMID = 15945092.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Intermediate Filament Proteins; 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 0 / alpha-Fetoproteins; 68238-35-7 / Keratins
  •  go-up   go-down


10. Bradley RF, Stewart JH 4th, Russell GB, Levine EA, Geisinger KR: Pseudomyxoma peritonei of appendiceal origin: a clinicopathologic analysis of 101 patients uniformly treated at a single institution, with literature review. Am J Surg Pathol; 2006 May;30(5):551-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pseudomyxoma peritonei is a clinical term for gelatinous ascites, usually secondary to an appendiceal tumor.
  • The pathologic classification of pseudomyxoma peritonei and its associated appendiceal tumors has been plagued with controversy and confusing terminology.
  • This is the largest pathologic series solely devoted to appendiceal neoplasia with gelatinous ascites.
  • After reviewing our data and the literature, mucinous carcinoma peritonei-low grade was applied to the low-grade histology of pseudomyxoma peritonei, including those cases referred to by some as DPAM in the same category as PMCA-I.
  • Cases that are moderately differentiated to poorly differentiated are classified as mucinous carcinoma peritonei-high grade.

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Surg Pathol. 2006 Nov;30(11):1483-4; author reply 1484-5 [17063093.001]
  • (PMID = 16699309.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K08 CA131482
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Fariña LA, Martínez MC: [Chylous ascites following radical nephrectomy. Conservative management whithout paracentesis]. Actas Urol Esp; 2009 Jun;33(6):703-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chylous ascites following radical nephrectomy. Conservative management whithout paracentesis].
  • [Transliterated title] Ascitis quilosa después de nefrectomía radical laparoscópica. Tratamiento conservador sin paracentesis.
  • INTRODUCTION: Chylous ascites is a rare complication after a number of abdominal and retroperitoneal surgeries.
  • PATIENT AND METHOD: A 60 year-old woman was treated with a laparoscopic radical nephrectomy for a 9.5x7.5 cm, pT2 pN0 tumor.
  • After six months of follow-up, no simptoms nor CT- signs of ascites or tumor recurred.
  • COMMENT: A conservative treatment, with diuretics, low lipids and salt diet, and eventually repeated paracentesis should be the first options for chylous ascites after nephrectomy.
  • In the last years, several laparoscopic techniques had been described to treat chylous ascites in a low invasive way, but the intrinsic difficulties of such a re-operation much be considered.
  • [MeSH-major] Chylous Ascites / etiology. Chylous Ascites / therapy. Nephrectomy / adverse effects

  • Genetic Alliance. consumer health - Chylous Ascites.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19711757.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas espanolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


12. Sakai M, Fonseca ES, Oloris SC, Matsuzaki P, Otake AH, Leite KR, Massoco CO, Dagli ML, Palermo-Neto J: Effects of peripheral-type benzodiazepine receptor ligands on Ehrlich tumor cell proliferation. Eur J Pharmacol; 2006 Nov 21;550(1-3):8-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of peripheral-type benzodiazepine receptor ligands on Ehrlich tumor cell proliferation.
  • Peripheral-type benzodiazepine receptor expression has been associated with tumor malignity, and its subcellular localization is important to define its function in tumor cells.
  • We investigated the presence of peripheral-type benzodiazepine receptors in Ehrlich tumor cells, and the in vitro effects of peripheral-type benzodiazepine receptors ligands on tumor cell proliferation.
  • Our results demonstrate the presence of peripheral-type benzodiazepine receptor in the nucleus of Ehrlich tumor cells (85.53+/-12.60%).
  • They also show that diazepam and Ro5-4864 (peripheral-type benzodiazepine receptor agonists) but not clonazepam (a molecule with low affinity for the peripheral-type benzodiazepine receptor) decreased the percentage of tumor cells in G0-G1 phases and increased that of cells in S-G2-M phases.
  • Altogether, these data suggest that the presence of peripheral-type benzodiazepine receptor within the nucleus of Ehrlich tumor cells is associated with tumor malignity and proliferation capacity.
  • [MeSH-major] Carcinoma, Ehrlich Tumor / drug therapy. Carcinoma, Ehrlich Tumor / pathology. Receptors, GABA-A / drug effects

  • Hazardous Substances Data Bank. 4-CHLORODIAZEPAM .
  • Hazardous Substances Data Bank. CLONAZEPAM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17027961.001).
  • [ISSN] 0014-2999
  • [Journal-full-title] European journal of pharmacology
  • [ISO-abbreviation] Eur. J. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Benzodiazepinones; 0 / GABA Modulators; 0 / Isoquinolines; 0 / Ligands; 0 / Receptors, GABA-A; 14439-61-3 / 4'-chlorodiazepam; 5PE9FDE8GB / Clonazepam; 85340-56-3 / PK 11195
  •  go-up   go-down


13. Olivotto M, Dello Sbarba P: Environmental restrictions within tumor ecosystems select for a convergent, hypoxia-resistant phenotype of cancer stem cells. Cell Cycle; 2008 Jan 15;7(2):176-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Environmental restrictions within tumor ecosystems select for a convergent, hypoxia-resistant phenotype of cancer stem cells.
  • Tumors are ecosystems which develop from stem cells endowed with unlimited self-renewal and genetic instability, under the effects of mutagenesis and natural selection imposed by environmental changes.
  • While changes and variations made possible by genetic instability are practically unlimited, the microenvironment progressively reduces those possibilities in the struggle for life imposed by hypoxia and nutrient shortage typical of tumor environments.
  • The metabolic orientation of this phenotype closely resembles the orientation of highly anaplastic ascites hepatomas, showing that, in restricted environments, stem cell recruitment to growth is limited by mitochondrial reoxidation of reducing equivalents produced in folate redox steps connected with purine synthesis.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18256528.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


14. Lin YG, Han LY, Kamat AA, Merritt WM, Landen CN, Deavers MT, Fletcher MS, Urbauer DL, Kinch MS, Sood AK: EphA2 overexpression is associated with angiogenesis in ovarian cancer. Cancer; 2007 Jan 15;109(2):332-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Based on EphA2's emerging role in angiogenesis, we hypothesized that tumors overexpressing EphA2 demonstrate greater microvessel density (MVD) and matrix metalloproteinase (MMP) expression.
  • METHODS: After Institutional Review Board (IRB) approval, 77 invasive epithelial ovarian tumors were analyzed for CD31, EphA2, MMP-2, MMP-9, and MT1-MMP expression.
  • EphA2 was overexpressed in 76% of tumors and was associated with advanced-stage disease (P < .001) and high-grade histology (P = .04).
  • High MVD was significantly associated with advanced stage (P < .001), presence of ascites (P < .001), and suboptimal surgical cytoreduction (P = .01).
  • MMP expression was scored separately in the stromal (percentage of tumors with high expression: MMP-2 = 43%; MMP-9 = 74%; MT1-MMP = 40%) and epithelial (percentage of tumors with high expression: MMP-2 = 52%; MMP-9 = 61%; MT1-MMP = 44%) compartments.
  • Endothelial cell EphA2 overexpression correlated with epithelial MMP-9 (P = .02), whereas EphA2 overexpression in tumor cells was significantly associated with high MVD (P = .002), as well as strong stromal and epithelial MMP-9 (P = .01 and P = .04, respectively), epithelial MMP-2 (P = .006), and epithelial MT1-MMP (P = .01) expression.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17154180.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 2P50CA083639-06A1; United States / NCI NIH HHS / CA / T32-CA101642-01-A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD31; EC 2.7.10.1 / Receptor, EphA2; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 3.4.24.80 / Matrix Metalloproteinase 14
  •  go-up   go-down


15. Elgqvist J, Andersson H, Bäck T, Claesson I, Hultborn R, Jensen H, Lindegren S, Olsson M, Palm S, Warnhammar E, Jacobsson L: Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab')2: therapeutic efficacy and myelotoxicity. Nucl Med Biol; 2006 Nov;33(8):1065-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eight weeks after the last injection, the animals were sacrificed and the presence of macro- and microscopic tumors and ascites was determined.
  • RESULTS: The tumor-free fractions of animals were 56% and 41% when treated with approximately 800 kBq and 3x approximately 267 kBq (211)At-MX35 F(ab')(2), respectively; 39% and 28% when treated with approximately 400 kBq and 3x approximately 133 kBq (211)At-MX35 F(ab')(2), respectively; and 17% and 22% when treated with approximately 50 kBq or 3x approximately 17 kBq (211)At-MX35 F(ab')(2), respectively.
  • [MeSH-minor] Animals. Cell Line, Tumor. Female. Humans. Mice

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17127181.001).
  • [ISSN] 0969-8051
  • [Journal-full-title] Nuclear medicine and biology
  • [ISO-abbreviation] Nucl. Med. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 211At-labeled monoclonal antibody MX35; 0 / Antibodies, Monoclonal; 0 / Immunoglobulin Fab Fragments; 0 / Organometallic Compounds
  •  go-up   go-down


16. Balzan S, Nagarajan G, Farges O, Galleano CZ, Dokmak S, Paugam C, Belghiti J: Safety of liver resections in obese and overweight patients. World J Surg; 2010 Dec;34(12):2960-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The new global epidemic, overweight and obesity, has a significant role in the etiology of liver tumors.
  • After major resection, major morbidity (Dindo-Clavien grade III or more) was more frequent in obese (57%) and overweight (54%) patients than in patients of normal body weight (35%; P < 0.05), including a higher rate of respiratory complications and ascites and longer intensive care unit (ICU) and hospital stays.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 2002 Jun;97(6):1480-8 [12094870.001]
  • [Cites] Br J Surg. 1998 Aug;85(8):1058-60 [9717995.001]
  • [Cites] Lancet. 2003 Jun 14;361(9374):2032-5 [12814714.001]
  • [Cites] Exp Clin Endocrinol Diabetes. 2006 May;114(5):257-61 [16804800.001]
  • [Cites] N Engl J Med. 2003 Apr 24;348(17):1625-38 [12711737.001]
  • [Cites] AJR Am J Roentgenol. 2000 Jul;175(1):149-52 [10882265.001]
  • [Cites] Hepatogastroenterology. 1993 Feb;40(1):14-6 [8462921.001]
  • [Cites] Ann Surg. 2007 Jun;245(6):923-30 [17522518.001]
  • [Cites] ANZ J Surg. 2007 Mar;77(3):135-41 [17305986.001]
  • [Cites] Ann Surg. 2003 May;237(5):686-91; discussion 691-3 [12724635.001]
  • [Cites] Clin Transplant. 1999 Feb;13(1 Pt 2):126-30 [10081649.001]
  • [Cites] Ann Surg. 2003 Feb;237(2):208-17 [12560779.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S97-103 [15508109.001]
  • [Cites] Hepatology. 1998 Jun;27(6):1567-71 [9620328.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):5016-23 [11431335.001]
  • [Cites] Hepatology. 2002 Jul;36(1):150-5 [12085359.001]
  • [Cites] Gastroenterology. 2002 Jul;123(1):134-40 [12105842.001]
  • [Cites] Am J Surg. 2004 Nov;188(5):495-9 [15546557.001]
  • [Cites] Arch Surg. 2003 Nov;138(11):1198-206; discussion 1206 [14609867.001]
  • [Cites] Ann Surg. 2007 Jan;245(1):20-30 [17197961.001]
  • [Cites] Ann Endocrinol (Paris). 2002 Apr;63(2 Pt 1):154-8 [11994680.001]
  • [Cites] Anesthesiology. 1992 Jan;76(1):3-15 [1729933.001]
  • [Cites] J Gastrointest Surg. 2003 Dec;7(8):1034-44 [14675713.001]
  • [Cites] N Engl J Med. 2002 Apr 18;346(16):1221-31 [11961152.001]
  • [Cites] Am J Surg. 2000 Apr;179(4):275-81 [10875985.001]
  • [Cites] Hepatogastroenterology. 1998 Mar-Apr;45(20):370-5 [9638409.001]
  • [Cites] Circulation. 2002 Mar 12;105(10):1257-67 [11889023.001]
  • [Cites] J Am Coll Surg. 2004 Jul;199(1):31-8 [15217626.001]
  • [Cites] Ann Surg. 2005 Dec;242(6):824-8, discussion 828-9 [16327492.001]
  • [Cites] BMC Public Health. 2008 Jun 05;8:200 [18533989.001]
  • [Cites] Hepatol Res. 2007 Sep;37 Suppl 2:S88-94 [17877502.001]
  • [Cites] Br J Surg. 1998 Feb;85(2):188-90 [9501812.001]
  • [Cites] Surgery. 2004 Jan;135(1):67-73 [14694302.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2005;12(1):1-3 [15754091.001]
  • [Cites] Ann Surg. 2002 Oct;236(4):397-406; discussion 406-7 [12368667.001]
  • [Cites] J Am Coll Surg. 2000 Jul;191(1):38-46 [10898182.001]
  • [Cites] Gut. 2005 Feb;54(2):289-96 [15647196.001]
  • [Cites] N Engl J Med. 2001 Nov 8;345(19):1359-67 [11794168.001]
  • [Cites] Br J Surg. 2006 Jan;93(1):67-72 [16273531.001]
  • [Cites] World J Gastroenterol. 2008 Mar 14;14(10):1553-8 [18330947.001]
  • [Cites] Semin Liver Dis. 2004 Nov;24(4):415-9 [15605309.001]
  • [Cites] Transplantation. 2003 Jul 15;76(1):158-63 [12865803.001]
  • [Cites] Arch Pediatr Adolesc Med. 2004 Jan;158(1):27-33 [14706954.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2005;12(5):351-5 [16258801.001]
  • [Cites] Ann Surg. 2005 May;241(5):821-6; discussion 826-8 [15849518.001]
  • [Cites] Ann Surg. 2004 Aug;240(2):205-13 [15273542.001]
  • [Cites] Am J Med. 1997 Mar;102(3):277-83 [9217597.001]
  • [Cites] J Gastrointest Surg. 1998 May-Jun;2(3):292-8 [9841987.001]
  • [Cites] Surg Endosc. 2007 Apr;21(4):619-24 [17285378.001]
  • [Cites] Hepatology. 1994 Jul;20(1 Pt 1):15-20 [8020885.001]
  • [Cites] Obes Surg. 2004 Feb;14(2):275-81 [15027438.001]
  • [Cites] World J Gastroenterol. 2007 Aug 21;13(31):4199-206 [17696248.001]
  • [Cites] J Hepatol. 2004 Jan;40(1):147-54 [14672626.001]
  • [Cites] JAMA. 2002 Oct 9;288(14):1723-7 [12365955.001]
  • [Cites] Circulation. 2008 Jul 22;118(4):428-64 [18591433.001]
  • [Cites] J Gastrointest Surg. 2002 Jan-Feb;6(1):88-94 [11986023.001]
  • [Cites] Ann Surg. 2009 Mar;249(3):414-9 [19247028.001]
  • [Cites] Ann Surg Oncol. 2008 Aug;15(8):2164-72 [18548313.001]
  • [Cites] ANZ J Surg. 2004 Dec;74(12):1082-97 [15574153.001]
  • [Cites] Gastroenterol Clin North Am. 2002 Jun;31(2):641-62 [12134622.001]
  • [Cites] Ann Surg. 2006 Aug;244(2):194-203 [16858181.001]
  • [Cites] Surgeon. 2007 Dec;5(6):339-42 [18080608.001]
  • (PMID = 20711580.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Upadhyay KK, Bhatt AN, Castro E, Mishra AK, Chuttani K, Dwarakanath BS, Schatz C, Le Meins JF, Misra A, Lecommandoux S: In vitro and in vivo evaluation of docetaxel loaded biodegradable polymersomes. Macromol Biosci; 2010 May 14;10(5):503-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, PolyDOC uptake in Ehrlich Ascites Tumor (EAT) tumor bearing mice was larger at each time point compared to DS, making such a polymer vesicle formulation an efficient drug nanocarrier for improved DOC cancer therapy.
  • [MeSH-minor] Animals. Capsules. Cell Line, Tumor. Female. Humans. Mice. Mice, Inbred BALB C. Rabbits

  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20232310.001).
  • [ISSN] 1616-5195
  • [Journal-full-title] Macromolecular bioscience
  • [ISO-abbreviation] Macromol Biosci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Capsules; 0 / Delayed-Action Preparations; 0 / Taxoids; 0 / poly(gamma-benzyl glutamate)-b-hyaluronan; 15H5577CQD / docetaxel; 25513-46-6 / Polyglutamic Acid; 9004-61-9 / Hyaluronic Acid
  •  go-up   go-down


18. Mustea A, Pirvulescu C, Könsgen D, Braicu EI, Yuan S, Sun P, Lichtenegger W, Sehouli J: Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer. Cytokine; 2008 Apr;42(1):77-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer.
  • Interleukin-1 alpha and beta (IL-1) and IL-1 RA are known to be critically involved in carcinogenesis and in various solid tumors.
  • There are limited data on expression of IL-1 alpha, beta and RA in serum and ascites in patients with advanced ovarian cancer.
  • Objectives of this study were to investigate the level of IL-1 alpha, IL-1 beta and IL-1 RA in serum and ascites from patients with ovarian cancer and their impact on the prognosis.
  • IL-1 alpha, beta and RA levels were analyzed in serum and ascites by ELISA technique.
  • The distribution of histological type of ovarian cancer was as follows: serous-papillary 43 (81.1%), 4 (7.5%) mucinous, 3 (5.7%) endometroid and 3 (5.7%) clear cell carcinoma.
  • The concentrations of IL-1 beta and RA in ascites or peritoneal fluid were significantly increased in patients with OC in comparison to the CG, for both cytokines (p<0.0001); also the concentration of IL-1 RA in serum was increased in OC (p=0.003) vs. CG.
  • An increased level of IL-1 beta in ascites correlated significantly with a poorer histopathological grading (p=0.038).
  • IL-1 RA concentration in ascites was correlated with advanced FIGO stage (p=0.049) and the IL-1 RA serum level with ascites volume (< or =500 ml vs. >500 ml) (p=0.046).
  • Patients with IL-1 RA level in ascites lower than the cut off value of 695.6 pg/ml showed a significant better progression-free median survival (24.6 vs. 12.8 months, p=0.008) and postoperative median overall survival (34.6 vs. 17 months, p=0.01) in comparison to patients with an IL-1 RA level in ascites higher than the cut off level.
  • Additionally, a higher expression of IL-1 beta in serum (p=0.004) and ascites (p=0.05) reduced significantly the progression-free survival.
  • In the multivariate analysis, expression of IL-1 RA in ascites was an independent prognostic factor for good progression-free and postoperative overall survival (HR, 0.39 95% CI, 0.18-0.83, p=0.01, HR, 0.36 95% CI, 0.16-0.8, p=0.01).
  • CONCLUSIONS: IL-1 RA levels in ascites lower than the cut off value of 695.6 pg/ml are associated with a significant improvement in postoperative and progression-free survival.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18329282.001).
  • [ISSN] 1096-0023
  • [Journal-full-title] Cytokine
  • [ISO-abbreviation] Cytokine
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / IL1RN protein, human; 0 / Interleukin 1 Receptor Antagonist Protein; 0 / Interleukin-1alpha; 0 / Interleukin-1beta
  •  go-up   go-down


19. Kryczek I, Lange A, Mottram P, Alvarez X, Cheng P, Hogan M, Moons L, Wei S, Zou L, Machelon V, Emilie D, Terrassa M, Lackner A, Curiel TJ, Carmeliet P, Zou W: CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res; 2005 Jan 15;65(2):465-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To examine tumor angiogenesis in the tumor microenvironment, we studied malignant ascites and tumors of patients with untreated ovarian carcinoma.
  • We observed that malignant ascites fluid induced potent in vivo neovascularization in Matrigel assay.
  • We detected a sizable amount of vascular endothelial cell growth factor (VEGF) in malignant ascites.
  • We show that ovarian tumors strongly express CXC chemokine stromal-derived factor (SDF-1/CXCL12).
  • Finally, we show that hypoxia synchronously induces tumor CXCL12 and VEGF production.
  • Therefore, hypoxia triggered tumor CXCL12 and VEGF form a synergistic angiogenic axis in vivo.
  • [MeSH-minor] Animals. Ascites / metabolism. Ascites / pathology. Cell Hypoxia / physiology. Cell Movement / drug effects. Cell Movement / physiology. Chemokine CXCL12. Drug Synergism. Endothelium, Vascular / cytology. Endothelium, Vascular / drug effects. Endothelium, Vascular / physiology. Female. Humans. Mice. Neovascularization, Pathologic / metabolism. Neovascularization, Pathologic / pathology. Recombinant Proteins / pharmacology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15695388.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA092562; United States / NCI NIH HHS / CA / CA100227
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CXCL12 protein, human; 0 / Chemokine CXCL12; 0 / Chemokines, CXC; 0 / Cxcl12 protein, mouse; 0 / Recombinant Proteins; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


20. Pomjanski N, Grote HJ, Sander O, Heikaus S, Müller KM, Böcking A: Early cytological diagnosis of diffuse malignant mesothelioma of the peritoneum: a case report. Diagn Cytopathol; 2008 Feb;36(2):120-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mesotheliomas are the most frequent primary malignant tumors of serosal cavities with a poor prognosis.
  • A definitive and early diagnosis on effusion samples is important, because recent advances in therapy for patients with mesothelioma may result in an improved outcome if they are applied to stage I disease.
  • We report a case of malignant peritoneal mesothelioma diagnosed repeatedly by cytology in ascites fluids 1.5 yr before the diagnosis was confirmed by biopsy histology.

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18181185.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Karpathiou G, Argiana E, Koutsopoulos A, Froudarakis ME: Response of a patient with pleural and peritoneal mesothelioma after second-line chemotherapy with lipoplatin and gemcitabine. Oncology; 2007;73(5-6):426-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diagnosis and staging of the disease was done by medical thoracoscopy with biopsies of the right pleura in December 2003, when he was treated with talc pleurodesis.
  • After 8 cycles, the patient presented renal toxicity limiting further cisplatinum chemotherapy and disease progression with peritoneal invasion of the tumor and ascites.

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2008 S. Karger AG, Basel.
  • (PMID = 18523361.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / lipoplatin; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


22. Presneau N, Shen Z, Provencher D, Mes-Masson AM, Tonin PN: Identification of novel variant, 1484delG in the 3'UTR of H3F3B, a member of the histone 3B replacement family, in ovarian tumors. Int J Oncol; 2005 Jun;26(6):1621-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of novel variant, 1484delG in the 3'UTR of H3F3B, a member of the histone 3B replacement family, in ovarian tumors.
  • Previous studies have implicated the chromosomal region at 17q25 as harboring tumor suppressor genes based on the frequent loss of heterozygosity (LOH) observed in epithelial ovarian cancers (EOC).
  • OV90 was derived from ascites fluid of an undifferentiated adenocarcinoma of ovarian origin.
  • The variant allele was identified in 1 of 65 (2%) healthy women with no prior history of cancer and in 5 participants with ovarian tumors comprising of 4 of 79 (5%) malignant EOC, none of 10 low malignancy potential tumors, and 1 of 8 (13%) benign tumors.
  • All carriers of the variant alleles were heterozygous and tumor samples did not exhibit preferential LOH of the normal allele.
  • The variant allele was identified in EOC samples of clear cell (1 of 20), mucinous (1 of 8), mixed cell (1 of 3) and undifferentiated (1 of 2) histopathological subtypes but none of 34 serous or 12 endometrioid subtype tumors.
  • One of 3 mucinous benign tumors also harbored the variant allele.
  • The functional significance of the variant is unknown, however its presence in rare subtypes of ovarian epithelial tumors warrants further investigation.
  • [MeSH-minor] Adult. Aged. Cell Line, Tumor. Chromosome Mapping. Chromosomes, Human, Pair 17. Female. Humans. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15870878.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / 3' Untranslated Regions; 0 / Histones
  •  go-up   go-down


23. Chen CF, Huang CJ, Kang WY, Hsieh JS: Experience with adjuvant chemotherapy for pseudomyxoma peritonei secondary to mucinous adenocarcinoma of the appendix with oxaliplatin/fluorouracil/leucovorin (FOLFOX4). World J Surg Oncol; 2008;6:118
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Pseudomyxoma peritonei (PMP) is a rare condition characterized by mucinous tumors, disseminated intra-peritoneal implants, and mucinous ascites.
  • A large amount of ascites was identified by abdominal computed tomography (CT) scan.
  • Paracentesis showed the appearance of sticky mucinous ascites.
  • There was a lot of mucinous ascites, one appendiceal tumor and multiple peritoneal implants disseminated from the subphrenic space to the recto-vesicle pouch.
  • We performed an excision of the appendiceal tumor combined with copious irrigation and debridement.

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Treat Res. 1996;81:105-19 [8834579.001]
  • [Cites] Am J Surg Pathol. 1995 Dec;19(12):1390-408 [7503361.001]
  • [Cites] Int J Gynecol Pathol. 1997 Jan;16(1):1-9 [8986525.001]
  • [Cites] Am J Pathol. 1999 Jun;154(6):1849-55 [10362811.001]
  • [Cites] Dis Colon Rectum. 2005 Jul;48(7):1372-9 [15909071.001]
  • [Cites] Lancet Oncol. 2006 Jan;7(1):69-76 [16389186.001]
  • [Cites] Am J Surg Pathol. 2006 May;30(5):551-9 [16699309.001]
  • [Cites] Ann Surg. 2007 Jan;245(1):104-9 [17197972.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):493-9 [17103067.001]
  • [Cites] Cancer Treat Rev. 2007 Apr;33(2):138-45 [17182192.001]
  • [Cites] Lancet. 2008 Mar 22;371(9617):1007-16 [18358928.001]
  • [Cites] Ann Surg Oncol. 1999 Dec;6(8):727-31 [10622499.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):2938-47 [10944126.001]
  • [Cites] Br J Surg. 2000 Oct;87(10):1414-8 [11044169.001]
  • [Cites] J Surg Oncol. 2000 Dec;75(4):270-4 [11135270.001]
  • [Cites] Gynecol Obstet Invest. 2001;51(2):73-80 [11223697.001]
  • [Cites] Eur J Surg Oncol. 2001 Apr;27(3):239-43 [11373099.001]
  • [Cites] Int J Gynecol Cancer. 2003 Jul-Aug;13(4):413-8 [12911716.001]
  • [Cites] Eur J Surg Oncol. 2003 Oct;29(8):682-8 [14511618.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3737-43 [14551293.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):23-30 [14665611.001]
  • [Cites] Eur J Gynaecol Oncol. 2004;25(4):411-4 [15285293.001]
  • [Cites] Cancer. 1975 Nov;36(5):1834-7 [1192367.001]
  • [Cites] Gynecol Oncol. 1985 Oct;22(2):257-9 [4054721.001]
  • [Cites] Am J Surg Pathol. 1991 May;15(5):415-29 [2035736.001]
  • [Cites] Cancer. 1992 Jul 15;70(2):396-401 [1319813.001]
  • [Cites] Am J Surg Pathol. 1994 Jun;18(6):591-603 [8179074.001]
  • [Cites] Hum Pathol. 1995 May;26(5):509-24 [7750935.001]
  • [Cites] Adv Surg. 1996;30:233-80 [8960339.001]
  • (PMID = 19014441.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2615010
  •  go-up   go-down


24. Guleng B, Tateishi K, Kanai F, Jazag A, Ohta M, Asaoka Y, Ijichi H, Tanaka Y, Imamura J, Ikenoue T, Fukushima Y, Morikane K, Miyagishi M, Taira K, Kawabe T, Omata M: Cancer-derived VEGF plays no role in malignant ascites formation in the mouse. World J Gastroenterol; 2005 Sep 21;11(35):5455-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer-derived VEGF plays no role in malignant ascites formation in the mouse.
  • AIM: Vascular endothelial growth factor (VEGF) is a potent mediator of peritoneal fluid accumulation following tumor progression.
  • This study investigated the role of VEGF secreted by cancerous cells in the formation of malignant ascites.
  • Malignant ascites formation in the mouse was analyzed by intraperitoneal injection of PancO2 cells expressing VEGF or with expression knockdown.
  • The volume of ascites following peritoneal expansion of the tumor in VEGF knockdown cells and control cells did not differ statistically in this in vivo study.
  • Moreover, the VEGF concentration in the ascites did not differ statistically.
  • CONCLUSION: Malignant ascites formation might be mediated by VEGF production in noncancerous tissues, such as stromal compartments.
  • An anti-VEGF strategy against malignant ascites could be applied to various tumors regardless of whether they secrete VEGF.
  • [MeSH-major] Ascites / etiology. Vascular Endothelial Growth Factor A / physiology
  • [MeSH-minor] Animals. Base Sequence. Cell Line, Tumor. Mice. Mice, Inbred C57BL. Molecular Sequence Data. Neoplasm Transplantation. Pancreatic Neoplasms / complications. Pancreatic Neoplasms / genetics. Pancreatic Neoplasms / secretion. RNA Interference. RNA, Small Interfering / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16222736.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / RNA, Small Interfering; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ PMC4320353
  •  go-up   go-down


25. Bakkum-Gamez JN, Aletti G, Lewis KA, Keeney GL, Thomas BM, Navarro-Teulon I, Cliby WA: Müllerian inhibiting substance type II receptor (MISIIR): a novel, tissue-specific target expressed by gynecologic cancers. Gynecol Oncol; 2008 Jan;108(1):141-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) Type II Receptor, bind, and are responsive to MIS.
  • Secondarily, we examined the impact of MISIIR expression on overall survival (OS) and disease-free survival (DFS) in a cohort of epithelial ovarian cancers (EOC).
  • We observed moderate or strong MISIIR expression via IHC in the majority of gynecologic cancers: EOC 69% (125/182), ovarian dysgerminomas 77% (17/22), endometrial cancers 75% (82/109), uterine malignant mixed Müllerian tumors (MMMT) 59% (30/51), uterine leiomyosarcomas (LMS) 52% (15/29), and endometrial stromal sarcomas (ESS) 22% (4/18).
  • Low levels of expression in select non-gynecologic tissues coupled with high expression in gynecologic malignancies make MISIIR an attractive target for novel therapeutics and tumor-directed imaging in the management of gynecologic cancers.
  • [MeSH-minor] Animals. Blotting, Western. CHO Cells. Cell Line, Tumor. Cricetinae. Cricetulus. Female. Humans. Immunohistochemistry. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate. Transfection

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17988723.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptors, Peptide; 0 / Receptors, Transforming Growth Factor beta; 0 / anti-Mullerian hormone receptor
  •  go-up   go-down


26. Yin RT, Peng ZL, Yang KX, Kang DY: [Survivin expression in ovarian carcinoma]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 Mar;37(2):215-7, 233
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Survivin expression in ovarian carcinoma].
  • OBJECTIVE: To explore the possible relationship between expression of survivin and molecular mechanisms in patients with ovarian carcinoma (OC).
  • METHODS: Survivin expressions in normal ovaries (n= 10), ovarian bordline tumors (n = 21), and ovarian serous cystadenomas (n = 38) were investigated by means of immunohistochemistry.
  • Survivin protein was found in cytoplasm and/or in nucleus of tumor cell.
  • Survivin expression was revealed in 42.9% (9/21) of ovarian bordline tumors; no significant correlation was observed between survivin expression and pathologic types or CA125 values (P > 0.05).
  • Survivin protein was found in 76.3% (29/38) of ovarian serous cystadenomas, displaying a significantly higher expression than that in bordline tumors (P < 0.05).
  • Survivin expression was positively correlated with tumor stage, histological grade and lymphonode metastasis (P < 0.05), whereas it was not significantly correlated with CA125 values, volume of ascites, and presence/absence of tumor cells in ascites (P > 0.05).
  • CONCLUSION: High expression of Survivin protein may be related with the differentiation and metastasis of epithelial ovarian carcinoma.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16608078.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger
  •  go-up   go-down


27. Esteves-Souza A, Lucio KA, Da Cunha AS, Da Cunha Pinto A, Da Silva Lima EL, Camara CA, Vargas MD, Gattass CR: Antitumoral activity of new polyamine-naphthoquinone conjugates. Oncol Rep; 2008 Jul;20(1):225-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All compounds were active against human lines of promyelocytic leukemia (HL-60), lung cancer (GLC4), Burkitt lymphoma (Daudi) and a mouse breast tumor (Ehrlich carcinoma), but only unprotected 6a-c showed activity against the human line of melanoma (MV-3).
  • In conclusion, spermidine-1,4-naphthoquinone conjugates exhibited an increase in activity compared with the natural products and induced apoptosis of tumor cell lines by a mechanism that is mediated, at least in part, by ROS production.
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cell Line, Tumor. DNA Fragmentation / drug effects. Humans. Mice. Reactive Oxygen Species / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18575741.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Naphthoquinones; 0 / Polyamines; 0 / Reactive Oxygen Species
  •  go-up   go-down


28. Zinchenko VP, Kasymov VA, Li VV, Kaĭmachnikov NP: [The calmodulin inhibitor R24571 induces a short-term Ca2+ entry and a pulse-like secretion of ATP in Ehrlich ascites tumor cells]. Biofizika; 2005 Nov-Dec;50(6):1055-69
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The calmodulin inhibitor R24571 induces a short-term Ca2+ entry and a pulse-like secretion of ATP in Ehrlich ascites tumor cells].
  • The properties of the Ca2+ channel induced by a calmodulin inhibitor in Ehrlich ascites tumor cells were investigated using fluorescent indicators Indo-1 and chlortetracycline.
  • [MeSH-major] Adenosine Triphosphate / secretion. Calcium / metabolism. Calcium Channels / metabolism. Calmodulin / antagonists & inhibitors. Carcinoma, Ehrlich Tumor / metabolism. Enzyme Inhibitors / pharmacology. Imidazoles / pharmacology

  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16358785.001).
  • [ISSN] 0006-3029
  • [Journal-full-title] Biofizika
  • [ISO-abbreviation] Biofizika
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Calcium Channels; 0 / Calmodulin; 0 / Enzyme Inhibitors; 0 / Imidazoles; 57265-65-3 / calmidazolium; 8L70Q75FXE / Adenosine Triphosphate; SY7Q814VUP / Calcium
  •  go-up   go-down


29. Gao YN, Jiang GQ, Liu JX, Tang WS, Chen LZ: [Preoperational misdiagnosis of extragastrointestinal stromal tumors as ovarian cancer: report of three cases with literature review]. Zhonghua Fu Chan Ke Za Zhi; 2005 May;40(5):339-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Preoperational misdiagnosis of extragastrointestinal stromal tumors as ovarian cancer: report of three cases with literature review].
  • OBJECTIVE: This report was to review how extragastrointestinal stromal tumor (EGIST) was similar to ovarian cancer, its differential diagnosis and treatment.
  • RESULTS: The cases of EGIST were presented with peritoneal and pelvic mass, or ascites, diagnosed as ovarian cancer at first, and finally diagnosed as EGIST by pathological method and positive CD(117) and CD(34) expression.
  • [MeSH-major] Diagnostic Errors. Gastrointestinal Stromal Tumors / diagnosis. Ovarian Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15938787.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD34; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Number-of-references] 8
  •  go-up   go-down


30. Watanabe T, Segami K, Sasaki T, Kawashima H, Enomoto T, Jinnouchi Y, Koizumi S, Tobe N, Sakurai J, Shimamura T, Suda T, Asakura T, Nakano H, Ichiroh T, Otsubo T: A rare case of concomitant huge exophytic gastrointestinal stromal tumor of the stomach and Kasabach-Merritt phenomenon. World J Surg Oncol; 2007;5:59
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare case of concomitant huge exophytic gastrointestinal stromal tumor of the stomach and Kasabach-Merritt phenomenon.
  • A physical examination revealed a 25 x 30 cm hard mass that was palpable in the middle and lower left abdomen minimal intrinsic mobility and massive ascites.
  • Due to this treatment, the platelet count recovered to 7.0 x 10(4); tumor resection was performed at 16 days after admission.
  • Laparotomy revealed a huge extraluminal tumor arising from the greater curvature of the stomach that measured 25 x 30 cm and had not ruptured into the peritoneal cavity or infiltrated other organs.
  • In cross section, the tumor appeared hard and homogenous with a small polycystic area.
  • CONCLUSION: Since the characteristic of tumor in this case was hypervascularity with bleeding and necrotic lesions, coagulopathy was thought to be caused by the trapping of platelets within a large vasculized tumor mass.
  • [MeSH-major] Disseminated Intravascular Coagulation / complications. Gastrointestinal Stromal Tumors / complications. Stomach Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2002 May;33(5):459-65 [12094370.001]
  • [Cites] Liver Transpl. 2002 Aug;8(8):721-4 [12149767.001]
  • [Cites] Breast. 2006 Apr;15(2):255-8 [16000250.001]
  • [Cites] Plast Reconstr Surg. 2006 Apr 15;117(5):81e-86e [16641700.001]
  • [Cites] N Engl J Med. 2002 Feb 28;346(9):683-93 [11870247.001]
  • [Cites] Ann Surg. 2000 Jan;231(1):51-8 [10636102.001]
  • [Cites] Pol J Pathol. 2003;54(1):3-24 [12817876.001]
  • [Cites] Hepatogastroenterology. 1996 Mar-Apr;43(8):422-6 [8714238.001]
  • [Cites] Hum Pathol. 1997 Feb;28(2):160-5 [9023396.001]
  • [Cites] Br J Surg. 1997 Mar;84(3):314-6 [9117293.001]
  • [Cites] Science. 1998 Jan 23;279(5350):577-80 [9438854.001]
  • [Cites] Plast Reconstr Surg. 1998 Sep;102(4):1158-62 [9734437.001]
  • [Cites] Arch Surg. 1999 Apr;134(4):407-11 [10199314.001]
  • [Cites] Gastric Cancer. 2004;7(4):260-5 [15616775.001]
  • [Cites] Dig Dis Sci. 2005 May;50(5):820-3 [15906751.001]
  • (PMID = 17540038.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1892781
  • [General-notes] NLM/ Original DateCompleted: 20070813
  •  go-up   go-down


31. Harlin H, Kuna TV, Peterson AC, Meng Y, Gajewski TF: Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites. Cancer Immunol Immunother; 2006 Oct;55(10):1185-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites.
  • Although melanoma tumors usually express antigens that can be recognized by T cells, immune-mediated tumor rejection is rare.
  • In many cases this is despite the presence of high frequencies of circulating tumor antigen-specific T cells, suggesting that tumor resistance downstream from T cell priming represents a critical barrier.
  • Analyzing T cells directly from the melanoma tumor microenvironment, as well as the nature of the microenvironment itself, is central for understanding the key downstream mechanisms of tumor escape.
  • In the current report we have studied tumor-associated lymphocytes from a patient with metastatic melanoma and large volume malignant ascites.
  • The ascites fluid showed abundant tumor cells that expressed common melanoma antigens and retained expression of class I MHC and antigen processing machinery.
  • The ascites fluid contained the chemokines CCL10, CCL15, and CCL18 which was associated with a large influx of activated T cells, including CD8(+) T cells recognizing HLA-A2 tetramer complexes with peptides from Melan-A and NA17-A.
  • However, several functional defects of these tumor antigen-specific T cells were seen, including poor production of IFN-gamma in response to peptide-pulsed APC or autologous tumor cells, and lack of expression of perforin.
  • Our observations suggest that, despite recruitment of large numbers of activated CD8(+) T cells into the tumor microenvironment, T cell hyporesponsiveness and additional negative regulatory mechanisms can limit the effector phase of the anti-tumor immune response.
  • [MeSH-major] Ascites / immunology. Ascitic Fluid / immunology. CD8-Positive T-Lymphocytes / immunology. Melanoma / immunology
  • [MeSH-minor] Adult. Antigen Presentation / immunology. Antigens, CD. Antigens, Differentiation / immunology. Antigens, Differentiation / therapeutic use. Antigens, Neoplasm / immunology. Antineoplastic Agents / immunology. Antineoplastic Agents / therapeutic use. CTLA-4 Antigen. Cancer Vaccines. Chemokines / immunology. Flow Cytometry. Histocompatibility Antigens Class II / immunology. Humans. Immunosuppressive Agents / immunology. Immunosuppressive Agents / therapeutic use. Immunotherapy. Interleukin-2 / immunology. Interleukin-2 / therapeutic use. Lymphocyte Activation / immunology. Male. Membrane Glycoproteins / immunology. Membrane Glycoproteins / therapeutic use. Reverse Transcriptase Polymerase Chain Reaction. T-Lymphocyte Subsets / immunology. Tumor Escape. gp100 Melanoma Antigen

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16468035.001).
  • [ISSN] 0340-7004
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA90575
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation; 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / CTLA-4 Antigen; 0 / CTLA4 protein, human; 0 / Cancer Vaccines; 0 / Chemokines; 0 / Histocompatibility Antigens Class II; 0 / Immunosuppressive Agents; 0 / Interleukin-2; 0 / Membrane Glycoproteins; 0 / PMEL protein, human; 0 / gp100 Melanoma Antigen
  •  go-up   go-down


32. Inoue T, Minami Y, Chung H, Hayaishi S, Ueda T, Tatsumi C, Takita M, Kitai S, Hatanaka K, Ishikawa E, Yada N, Hagiwara S, Ueshima K, Kudo M: Radiofrequency ablation for hepatocellular carcinoma: assistant techniques for difficult cases. Oncology; 2010 Jul;78 Suppl 1:94-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiofrequency ablation for hepatocellular carcinoma: assistant techniques for difficult cases.
  • PURPOSE: To confirm the safety and effectiveness of techniques to assist radiofrequency ablation (RFA) for difficult cases, we retrospectively evaluated successful treatment rates, early complications and local tumor progressions.
  • Artificial ascites-assisted ablation was performed on 11 patients with 13 nodules.
  • When the tumors were not well visualized with conventional B-mode ultrasonography (US), contrast-enhanced US-assisted ablation with Levovist or Sonazoid or virtual CT sonography-assisted ablation was performed.
  • For RFA with artificial pleural effusion, artificial ascites and ENBD, complete response was confirmed in all cases.
  • Local tumor recurrence was investigated in 377 nodules of 245 patients, and 69 (18%) nodules were positive.
  • Tumor recurrences in each assisted technique were 14.7% in artificial pleural effusion cases, 7% in artificial ascites, 12.5% in ENBD tube cases, 31% in virtual CT sonography, and 8.5% in contrast-enhanced US.
  • CONCLUSION: Although local tumor progression needs to be carefully monitored, assisted techniques of RFA for difficult cases are well tolerated and expand the indications of RFA.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Catheter Ablation. Liver Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 S. Karger AG, Basel.
  • (PMID = 20616590.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


33. Glisić A, Atanacković J: Krukenberg tumor in pregnancy. The lethal outcome. Pathol Oncol Res; 2006;12(2):108-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Krukenberg tumor in pregnancy. The lethal outcome.
  • Krukenberg tumor refers to gastrointestinal cancer metastatic to the ovaries and its prognosis is uniformly poor.
  • She presented with a large abdominopelvic tumor.
  • At laparotomy, bilateral ovarian tumors, ascites and gastric cancer located at the cardia and the lesser curvature invading the serosa were identified.
  • Histological examination of the specimen yielded diagnosis of Krukenberg tumor.
  • [MeSH-major] Krukenberg Tumor / secondary. Ovarian Neoplasms / secondary. Pregnancy Complications, Neoplastic / pathology. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Gynecol Obstet. 1996;258(3):151-4 [8781704.001]
  • [Cites] Zhonghua Yi Xue Za Zhi (Taipei). 1994 Dec;54(6):424-7 [7850685.001]
  • [Cites] Prim Care Update Ob Gyns. 1998 Jul 1;5(4):157-158 [10838292.001]
  • [Cites] Eur J Gynaecol Oncol. 2000;21(1):58-60 [10726620.001]
  • [Cites] Gynecol Oncol. 1996 Apr;61(1):153-5 [8626106.001]
  • [Cites] Arch Gynecol Obstet. 2003 Jan;267(3):148-52 [12580154.001]
  • [Cites] Acta Anaesthesiol Scand. 2002 Nov;46(10):1272-5 [12421201.001]
  • [Cites] Gastroenterol Hepatol. 2001 Feb;24(2):63-5 [11247291.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1995 Oct;62(2):251-2 [8582506.001]
  • [Cites] Ultrasound Obstet Gynecol. 1998 Jun;11(6):459-60 [9674097.001]
  • [Cites] Gynecol Obstet Invest. 1999;48(1):61-5 [10394095.001]
  • [Cites] Eur J Gynaecol Oncol. 1995;16(1):59-64 [7744119.001]
  • (PMID = 16799713.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


34. Yang JH, Shi YF, Cheng Q, Deng L: Expression and localization of aquaporin-5 in the epithelial ovarian tumors. Gynecol Oncol; 2006 Feb;100(2):294-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and localization of aquaporin-5 in the epithelial ovarian tumors.
  • OBJECTIVE: To investigate the expression and localization of aquaporin-5 (AQP5) in epithelial ovarian tumors and its clinic significance.
  • METHODS: The expression of AQP5 protein and mRNA in 65 cases epithelial ovarian tumors and 13 cases normal tissue were measured by immunohistochemical technique, Western blotting and RT-PCR, respectively.
  • RESULTS: AQP5 is mainly localized in the basolateral membranes of benign tumor cells, the apical and basolateral membrane of borderline cells and scattered in the membrane of malignant cells and almost no or weak staining in normal ovarian epithelium.
  • The AQP5 expression in ovarian malignant and borderline tumors was significantly higher than that of benign tumors (P < 0.05) and normal tissue (P < 0.05).
  • Of all the epithelial ovarian malignant tumors, the AQP5 expression in cases with ascites volume more than 1000 ml was higher than that of ascites volume less than 500 ml (P < 0.05).
  • There is a positive correlation between ascites amount and the expression of AQP5 protein and mRNA (P < 0.05), as well as lymph node metastasis and the expression of AQP5 protein and mRNA (P < 0.05).
  • CONCLUSION: The data suggest that overexpression of AQP5 play an important role in tumorigenesis of epithelial ovarian tumors, which may be related to the ascites formation of ovarian carcinoma.
  • [MeSH-minor] Adolescent. Adult. Aged. Ascites / metabolism. Ascites / pathology. Blotting, Western. Epithelial Cells / pathology. Female. Humans. Immunohistochemistry. Lymphatic Metastasis. Middle Aged. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16242760.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AQP5 protein, human; 0 / Aquaporin 5; 0 / RNA, Messenger
  •  go-up   go-down


35. Jeschke U, Mylonas I, Kunert-Keil C, Stahn R, Scholz C, Janni W, Kuhn C, Schröder E, Mayr D, Friese K: Immunohistochemistry, glycosylation and immunosuppression of glycodelin in human ovarian cancer. Histochem Cell Biol; 2009 Feb;131(2):283-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • With a Gd peptide antibody, derived from a 15 amino acid sequence of human Gd and in situ hybridization experiments, the expression of Gd in serous, mucinous, endometrioid and clear cell ovarian tumors was identified.
  • In addition, Gd is expressed in granulose cell tumors, a non-epithelial form of ovarian cancer.
  • Furthermore, Gd was purified from ascites fluid of ovarian cancer patients.
  • Ascites Gd showed significant differences in its structure of sialyl Lewis-type oligosaccharides compared to GdA.
  • Additionally, ascites Gd inhibits IL-2 stimulated proliferation of peripheral blood leucocytes and inhibits adhesion of SLe(X)-positive cells to E-selectin.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Reprod Immunol. 1991 Dec;26(4):137-42 [1840727.001]
  • [Cites] Glycobiology. 1998 Nov;8(11):1053-64 [9751792.001]
  • [Cites] Am J Pathol. 1996 May;148(5):1435-43 [8623915.001]
  • [Cites] Anticancer Res. 2003 Mar-Apr;23 (2A):1119-25 [12820358.001]
  • [Cites] Int J Oncol. 1998 Mar;12(3):569-76 [9472094.001]
  • [Cites] J Perinat Med. 2005;33(3):212-8 [15914343.001]
  • [Cites] Virchows Arch. 2005 Apr;446(4):360-8 [15756591.001]
  • [Cites] Biol Reprod. 2003 Nov;69(5):1545-51 [12826581.001]
  • [Cites] Arch Gynecol Obstet. 2003 Aug;268(3):162-7 [12942243.001]
  • [Cites] Breast Cancer Res Treat. 2007 Jan;101(1):17-25 [16807671.001]
  • [Cites] Vopr Onkol. 1990;36(7):845-9 [2205044.001]
  • [Cites] Int J Gynecol Cancer. 2001 May-Jun;11(3):173-9 [11437921.001]
  • [Cites] Endocrinology. 2007 Feb;148(2):896-902 [17068141.001]
  • [Cites] Mol Hum Reprod. 1996 Oct;2(10 ):759-65 [9239694.001]
  • [Cites] J Biol Chem. 1995 Oct 13;270(41):24116-26 [7592613.001]
  • [Cites] Cell Immunol. 2003 Apr;222(2):156-63 [12826085.001]
  • [Cites] Fertil Steril. 1998 Mar;69(3):543-8 [9531894.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Dec;85(23 ):8845-9 [3194393.001]
  • [Cites] Gynecol Obstet Invest. 2004;58(4):207-11 [15297810.001]
  • [Cites] J Biol Chem. 1985 Oct 25;260(24):12957-67 [3863814.001]
  • [Cites] Cancer Res. 1997 Dec 1;57(23):5201-6 [9393734.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13789-94 [12370411.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 31;98 (16):9265-70 [11459932.001]
  • [Cites] Arch Androl. 1984;12 Suppl:59-67 [6398989.001]
  • [Cites] Endocrinology. 1986 May;118(5):1782-6 [3516653.001]
  • [Cites] Z Geburtshilfe Neonatol. 2005 Apr;209(2):59-64 [15852231.001]
  • [Cites] Anticancer Res. 2005 May-Jun;25(3A):1581-9 [16033064.001]
  • [Cites] Fertil Steril. 1995 Feb;63(2):377-83 [7531163.001]
  • [Cites] Cancer. 1998 Mar 1;82(5):893-901 [9486579.001]
  • [Cites] Clin Exp Immunol. 1989 Aug;77(2):252-6 [2789118.001]
  • [Cites] Blood. 1994 Jul 15;84(2):467-73 [8025274.001]
  • [Cites] Histochem Cell Biol. 2003 May;119(5):345-54 [12743827.001]
  • [Cites] Glycobiology. 1994 Apr;4(2):221-5 [7519910.001]
  • [Cites] J Immunol Methods. 1991 Jan 24;136(1):85-90 [1995715.001]
  • [Cites] J Reprod Immunol. 1988 Jun;13(1):31-9 [3418616.001]
  • [Cites] J Biol Chem. 2001 Jul 27;276(30):28268-73 [11325960.001]
  • [Cites] J Biol Chem. 2003 Apr 18;278(16):14059-65 [12556471.001]
  • [Cites] Anticancer Res. 2005 May-Jun;25(3A):1639-44 [16033074.001]
  • [Cites] J Mol Endocrinol. 1999 Aug;23 (1):57-66 [10425447.001]
  • [Cites] Acta Endocrinol (Copenh). 1986 Jun;112(2):271-7 [3526786.001]
  • [Cites] Cells Tissues Organs. 2001;168(1-2):113-21 [11114593.001]
  • [Cites] J Clin Endocrinol Metab. 1981 May;52(5):1006-8 [7014586.001]
  • [Cites] Fertil Steril. 2006 Nov;86(5):1488-97 [17070198.001]
  • [Cites] Placenta Suppl. 1982;4:67-81 [6085895.001]
  • [Cites] J Mol Histol. 2005 Feb;36(1-2):111-7 [15704005.001]
  • [Cites] Arch Gynecol Obstet. 1996;258(4):165-9 [8844133.001]
  • [Cites] Endocr Rev. 2002 Aug;23 (4):401-30 [12202458.001]
  • [Cites] Cell Immunol. 1999 Jan 10;191(1):26-33 [9918684.001]
  • [Cites] Int J Cancer. 1999 Dec 10;83(6):738-42 [10597188.001]
  • [Cites] Histochem Cell Biol. 2005 Jun;123(6):631-7 [15889266.001]
  • [Cites] Hum Reprod. 2007 Oct;22(10 ):2615-22 [17720699.001]
  • [Cites] J Reprod Fertil Suppl. 1988;36:127-41 [3057195.001]
  • [Cites] Lab Invest. 1997 Dec;77(6):565-73 [9426393.001]
  • [Cites] Anticancer Res. 2007 Jul-Aug;27(4A):2023-5 [17649816.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6258-64 [14559812.001]
  • [Cites] J Exp Med. 2003 Oct 20;198(8):1201-12 [14568979.001]
  • [Cites] Histochem Cell Biol. 2002 Mar;117(3):219-26 [11914919.001]
  • [Cites] Endocrinology. 2005 Dec;146(12 ):5365-73 [16123169.001]
  • [Cites] J Biol Chem. 2001 May 18;276(20):17101-5 [11278680.001]
  • [Cites] Histochem Cell Biol. 2000 Nov;114(5):405-11 [11151410.001]
  • [Cites] Immunology. 1990 Feb;69(2):277-81 [2307483.001]
  • [Cites] J Biol Chem. 1996 Dec 13;271(50):32159-67 [8943270.001]
  • [Cites] EMBO J. 1999 Mar 15;18(6):1516-25 [10075923.001]
  • [Cites] Lancet. 1987 Mar 14;1(8533):593-5 [2881133.001]
  • [Cites] Oncol Rep. 2005 Mar;13(3):413-9 [15706409.001]
  • [Cites] Int J Cancer. 1997 Jun 20;74(3):296-300 [9221808.001]
  • [Cites] Glycobiology. 1998 Apr;8(4):311-19 [9499378.001]
  • [Cites] Curr Top Microbiol Immunol. 2002;270:121-44 [12467248.001]
  • [Cites] Tumour Biol. 1992;13(3):175-9 [1626182.001]
  • (PMID = 18853174.001).
  • [ISSN] 1432-119X
  • [Journal-full-title] Histochemistry and cell biology
  • [ISO-abbreviation] Histochem. Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / 5-acetylneuraminyl-(2-3)-galactosyl-(1-4)-(fucopyranosyl-(1-3))-N-acetylglucosamine; 0 / Glycodelin; 0 / Glycoproteins; 0 / Oligosaccharides; 0 / PAEP protein, human; 0 / Pregnancy Proteins
  •  go-up   go-down


36. Tsukioka G, Kakizaki S, Sohara N, Sato K, Takagi H, Arai H, Abe T, Toyoda M, Katakai K, Kojima A, Yamazaki Y, Otsuka T, Matsuzaki Y, Makita F, Kanda D, Horiuchi K, Hamada T, Kaneko M, Suzuki H, Mori M: Hepatocellular carcinoma in extremely elderly patients: an analysis of clinical characteristics, prognosis and patient survival. World J Gastroenterol; 2006 Jan 7;12(1):48-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular carcinoma in extremely elderly patients: an analysis of clinical characteristics, prognosis and patient survival.
  • AIM: To identify the clinical and prognostic features of patients with hepatocellular carcinoma (HCC) aged 80 years or more.
  • There were no significant differences in the following parameters: diameter and number of tumors, Child-Pugh grading, tumor staging, presence of portal thrombosis or ascites, and positive rate for HCVAb.
  • [MeSH-major] Carcinoma, Hepatocellular / mortality. Liver Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatogastroenterology. 2003 Nov-Dec;50(54):1872-7 [14696422.001]
  • [Cites] Hepatogastroenterology. 2003 Nov-Dec;50(54):2022-7 [14696457.001]
  • [Cites] J Gastroenterol Hepatol. 2004 Aug;19(8):859-65 [15242487.001]
  • [Cites] Am J Surg. 1988 Feb;155(2):238-41 [2829639.001]
  • [Cites] Med Pediatr Oncol. 1994;22(2):84-7 [7505049.001]
  • [Cites] Age Ageing. 1994 Jan;23(1):22-7 [8010166.001]
  • [Cites] Hepatogastroenterology. 2001 Nov-Dec;48(42):1692-6 [11813602.001]
  • [Cites] Cancer. 1994 Oct 15;74(8):2234-8 [7922974.001]
  • [Cites] Ann Surg. 1995 Mar;221(3):308-14 [7536406.001]
  • [Cites] World J Surg. 1998 Apr;22(4):406-12 [9523524.001]
  • [Cites] Am J Gastroenterol. 1999 Sep;94(9):2460-6 [10484009.001]
  • [Cites] J Hepatol. 1999 Nov;31(5):860-6 [10580583.001]
  • [Cites] Br J Cancer. 1994 Oct;70(4):690-3 [7917919.001]
  • (PMID = 16440416.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4077478
  •  go-up   go-down


37. Nersesyan A, Muradyan R, Arsenyan F: The influence of three newly synthesized pyrimidine-containing compounds on micronucleus induction and tumor growth. J BUON; 2007 Oct-Dec;12(4):521-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The influence of three newly synthesized pyrimidine-containing compounds on micronucleus induction and tumor growth.
  • MATERIALS AND METHODS: The compounds were tested for their toxicity and MN-inducing activities in HeLa tumor cell line and Swiss mice.
  • Antitumor activity was studied on mouse Ehrlich ascites carcinoma (EAC) by means of evaluation of tumor (ascites) volume and mean lifespan (MLS).
  • One day after the last injection half of the mice with EAC were sacrificed and antitumor activity was assessed by means of ascites volume inhibition.
  • Also the frequency of MN and the number of viable cells (by means of trypan blue exclusion) was evaluated in ascites.
  • Antitumor effect of combined action of the compounds with CP (based on the ascites volume) was increased compared with CP effect by 17.7% (p >0.05; DGS-658 and DGS-664A) and 28.2% (p <0.001; DGS- 666).
  • [MeSH-minor] Animals. Carcinoma, Ehrlich Tumor / pathology. Cell Proliferation / drug effects. HeLa Cells. Heterocyclic Compounds, 2-Ring. Humans. Mice. Micronuclei, Chromosome-Defective / chemically induced. Micronucleus Tests

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18067211.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DGS-658; 0 / DGS-664A; 0 / DGS-666; 0 / Heterocyclic Compounds, 2-Ring; 0 / Pyrazoles; 0 / Pyrimidines; K8CXK5Q32L / pyrimidine
  •  go-up   go-down


38. Meng FP, Ding J, Yu ZC, Han QL, Guo CC, Liu N, Fan DM: Oral attenuated Salmonella typhimurium vaccine against MG7-Ag mimotope of gastric cancer. World J Gastroenterol; 2005 Mar 28;11(12):1833-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ehrlich ascites carcinoma cells expressing MG7-Ag were used in tumor challenge assay as a model to evaluate the protective effect of the vaccine.
  • Two weeks after tumor challenge, 1 in 5 immunized mice was tumor free, while all the mice in the control group presented tumor.
  • It can induce significant humoral immunity against tumors in mice, and has some protective effects.
  • [MeSH-major] Antigens, Neoplasm / immunology. Cancer Vaccines / pharmacology. Carcinoma, Ehrlich Tumor / prevention & control. Salmonella typhimurium / immunology. Stomach Neoplasms / prevention & control

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15793876.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cancer Vaccines; 0 / Hepatitis B Core Antigens
  • [Other-IDs] NLM/ PMC4305886
  •  go-up   go-down


39. Kim KH, Xie Y, Tytler EM, Woessner R, Mor G, Alvero AB: KSP inhibitor ARRY-520 as a substitute for Paclitaxel in Type I ovarian cancer cells. J Transl Med; 2009 Jul 20;7:63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: We previously described a sub-population of epithelial ovarian cancer (EOC) cells with a functional TLR-4/MyD88/NF-kappaB pathway (Type I EOC cells), which confers the capacity to respond to Paclitaxel, a known TLR-4 ligand, by enhancing NF-kappaB activity and upregulating cytokine secretion - events that are known to promote tumor progression.
  • METHODS: EOC cells isolated from either ascites or tumor tissue were treated with increasing concentrations of ARRY-520 or Paclitaxel and cell viability determined.
  • IL-6), which promote chemoresistance and tumor progression.
  • ARRY-520 has similar anti-tumor activity in EOC cells as that of Paclitaxel.
  • However, unlike Paclitaxel, it does not induce these pro-tumor effects in Type I cells.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cytokine. 2000 Jun;12(6):547-54 [10843728.001]
  • [Cites] Eur J Immunol. 2001 Aug;31(8):2448-57 [11500829.001]
  • [Cites] Cancer Treat Res. 2002;107:99-118 [11775463.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1 Suppl 1):3-8 [11840413.001]
  • [Cites] Sci STKE. 1999 Oct 26;1999(5):RE1 [11865184.001]
  • [Cites] J Biol Chem. 2002 Apr 19;277(16):13430-7 [11832478.001]
  • [Cites] Science. 2002 Aug 23;297(5585):1352-4 [12193789.001]
  • [Cites] Oncogene. 2003 May 1;22(17):2611-20 [12730675.001]
  • [Cites] Cancer Lett. 2004 Apr 8;206(2):193-9 [15013524.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3276-80 [15126370.001]
  • [Cites] J Biol Chem. 2004 Aug 13;279(33):35047-52 [15173176.001]
  • [Cites] Nature. 2004 Sep 23;431(7007):461-6 [15329734.001]
  • [Cites] Cancer Res. 1987 Jan 15;47(2):414-8 [3539322.001]
  • [Cites] Cell. 1995 Dec 29;83(7):1159-69 [8548803.001]
  • [Cites] J Soc Gynecol Investig. 1994 Jul-Sep;1(3):181-90 [9419769.001]
  • [Cites] Adv Cancer Res. 1998;74:49-139 [9561267.001]
  • [Cites] EMBO J. 2005 Oct 19;24(20):3532-42 [16193064.001]
  • [Cites] Cancer. 2006 Feb 1;106(3):599-608 [16388521.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3859-68 [16585214.001]
  • [Cites] Cytokine Growth Factor Rev. 2006 Oct;17(5):325-37 [16931107.001]
  • [Cites] Mol Cell Biol. 2007 Jan;27(2):689-98 [17101792.001]
  • [Cites] Cancer Res. 2007 Jan 1;67(1):237-45 [17210704.001]
  • [Cites] Methods Find Exp Clin Pharmacol. 2007 Nov;29(9):625-55 [18193114.001]
  • [Cites] Cancer Lett. 2008 Aug 28;267(2):182-8 [18479806.001]
  • [Cites] Oncogene. 2008 Aug 7;27(34):4712-23 [18408758.001]
  • [Cites] Anticancer Agents Med Chem. 2008 Aug;8(6):698-704 [18690830.001]
  • [Cites] Cell Cycle. 2009 Jan 1;8(1):158-66 [19158483.001]
  • [Cites] Cancer. 2009 Jul 15;115(14):3204-16 [19472400.001]
  • [Cites] J Biol Chem. 2001 Jun 1;276(22):19555-64 [11278851.001]
  • (PMID = 19619321.001).
  • [ISSN] 1479-5876
  • [Journal-full-title] Journal of translational medicine
  • [ISO-abbreviation] J Transl Med
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA118678-03; United States / NCI NIH HHS / CA / R01 CA118678; United States / NCI NIH HHS / CA / R01 CA118678-03; United States / NCI NIH HHS / CA / R01CA118678
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ARRY 520; 0 / Antineoplastic Agents, Phytogenic; 0 / Enzyme Inhibitors; 0 / KIF11 protein, human; 0 / Thiadiazoles; EC 1.13.12.- / Luciferases; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 7; EC 3.4.22.- / Caspase 9; EC 3.6.1.- / Kinesin; P88XT4IS4D / Paclitaxel
  • [Other-IDs] NLM/ PMC2719595
  •  go-up   go-down


40. Tanaka H, Kageyama K, Kusumoto K, Asada R, Miwa N: Antitumor and anti-invasive effects of diverse new macrocyclic lactones, alkylolides and alkenylolides, and their enhancement by hyperthermia. Oncol Rep; 2007 Nov;18(5):1257-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Alkylolides and alkenylolides of 198-254 Da such as hexadecan-16-olide and 9-hexadecen-16-olide were chemically synthesized in the present study as new macrocyclic lactones that are structurally different from widespread natural macrocyclic lactones including bryostatin (887 Da) and rhizoxin (613 Da), and were investigated for antitumor activity to Ehrlich ascites tumor cells by mitochondrial dehydroganase-based WST-1 assay and dye-exclusion assay.
  • H16:0 also exhibited the most inhibitory activity to tumor invasion in addition to the highest carcinostatic activity.
  • Thus diverse alkyl-/alkenylolides, may be potent multi-applicable anticancer agents in terms of either dual inhibitory activities against both tumor progression and invasion or hyperthermia-combined therapy.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Carcinoma, Ehrlich Tumor / drug therapy. Fibrosarcoma / drug therapy. Hyperthermia, Induced. Lactones / pharmacology
  • [MeSH-minor] Animals. Bryostatins / pharmacology. Cell Survival / drug effects. Combined Modality Therapy. Humans. Macrolides / pharmacology. Neoplasm Invasiveness. Tumor Cells, Cultured / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17914582.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Bryostatins; 0 / Lactones; 0 / Macrolides; 37O2X55Y9E / bryostatin 1; 90996-54-6 / rhizoxin
  •  go-up   go-down


41. Bartolotta TV, Taibbi A, Galia M, Cannella I, Lo Re G, Sparacia G, Midiri M, Lagalla R: Gastrointestinal stromal tumour: 40-row multislice computed tomography findings. Radiol Med; 2006 Aug;111(5):651-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrointestinal stromal tumour: 40-row multislice computed tomography findings.
  • PURPOSE: The purpose of this study was to describe the findings and evaluate the role of multidetector (40-slice) computed tomography (MDCT) in the preoperative assessment of gastrointestinal stromal tumours (GISTs).
  • Two experienced radiologists reviewed the CT findings to evaluate lesion site, size, margins, attenuation, growth pattern, enhancement pattern, ascites, lymphadenopathy, direct invasion to adjacent organs and distant metastasis.
  • Direct invasion to adjacent organs (n=3), ascites (n=3), and liver (n=1) and peritoneal (n=1) metastases were also detected.
  • [MeSH-major] Gastrointestinal Stromal Tumors / radiography. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16791466.001).
  • [ISSN] 0033-8362
  • [Journal-full-title] La Radiologia medica
  • [ISO-abbreviation] Radiol Med
  • [Language] eng; ita
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


42. Lingaraju SM, Keshavaiah K, Salimath BP: Inhibition of in vivo angiogenesis by Anacardium occidentale L. involves repression of the cytokine VEGF gene expression. Drug Discov Ther; 2008 Aug;2(4):234-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lethal tumor growth and progression cannot occur without angiogenesis, which facilitates cancer cell proliferation, survival, and dissemination.
  • In this study, we have tested the crude ethanolic extract of the leaves of Anacardium occidentale Linn, on Ehrlich ascites tumor cells (EAT) in vivo and in vitro.
  • The extract inhibited cell proliferation of different tumor cells such as EAT, BeWo, and MCF-7 in vitro in a dose-dependent manner and it reduced the VEGF level in the ascites of treated mice.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22504635.001).
  • [ISSN] 1881-7831
  • [Journal-full-title] Drug discoveries & therapeutics
  • [ISO-abbreviation] Drug Discov Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


43. Filipek A: S100A6 and CacyBP/SIP - two proteins discovered in ehrlich ascites tumor cells that are potentially involved in the degradation of beta-catenin. Chemotherapy; 2006;52(1):32-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] S100A6 and CacyBP/SIP - two proteins discovered in ehrlich ascites tumor cells that are potentially involved in the degradation of beta-catenin.
  • Originally, S100A6 was purified from Ehrlich ascites tumor cells, but later, it was found in fibroblasts, epithelial cells and in tumor cells with high metastatic activity.
  • When Ca(2+)-dependent interaction of S100A6 with target proteins was studied in Ehrlich ascites tumor cells, a novel protein, now called CacyBP/SIP, was discovered.
  • [MeSH-major] Calcium-Binding Proteins / metabolism. Carcinoma, Ehrlich Tumor / metabolism. beta Catenin / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel.
  • (PMID = 16340196.001).
  • [ISSN] 0009-3157
  • [Journal-full-title] Chemotherapy
  • [ISO-abbreviation] Chemotherapy
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Calcium-Binding Proteins; 0 / beta Catenin
  • [Number-of-references] 5
  •  go-up   go-down


44. Duluc D, Corvaisier M, Blanchard S, Catala L, Descamps P, Gamelin E, Ponsoda S, Delneste Y, Hebbar M, Jeannin P: Interferon-gamma reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages. Int J Cancer; 2009 Jul 15;125(2):367-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interferon-gamma reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages.
  • Tumor-associated macrophages (TAM) are M2d-polarized cells (IL-10(high), IL-12(low), ILT3(high), CD86(low)) that accumulate in tumor microenvironment.
  • TAM inhibit antitumor T lymphocyte generation and function, contribute to tumor tolerance and are trophic for tumors.
  • Upon IFNgamma exposure, TAM purified from ovarian cancer ascites recover a M1 phenotype (IL-10(low), IL-12(high)), express high levels of CD86 and low levels of ILT3, enhance the proliferation of CD4(+) T lymphocytes and potentiate the cytotoxic properties of a MelanA-specific CD8(+) T cell clone.
  • IFNgamma-treated TAM also secreted reduced levels of mediators promoting suppressive T cell accumulation (CCL18) and trophic for tumors (VEGF and MMP9).
  • In the presence of ovarian ascites, IFNgamma skewed monocyte differentiation from TAM-like cells to M1-polarized immunostimulatory macrophages.
  • These data highlight that IFNgamma used locally at the tumor site could potentiate the efficacy of antitumor immunotherapies based on the generation of effector T cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 UICC.
  • (PMID = 19378341.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 82115-62-6 / Interferon-gamma
  •  go-up   go-down


45. Chay D, Cho H, Lim BJ, Kang ES, Oh YJ, Choi SM, Kim BW, Kim YT, Kim JH: ER-60 (PDIA3) is highly expressed in a newly established serous ovarian cancer cell line, YDOV-139. Int J Oncol; 2010 Aug;37(2):399-412
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The YDOV-139 cell line was established using ascites samples from a 67-year-old Korean woman with recurrent ovarian cancer, and was characterized with respect to various biological and genetic features.
  • Gene expression profiles were analyzed using cDNA microarrays, and proteomic evaluation was performed by two-dimensional gel electrophoresis (2-DE) and matrix-assisted laser desorption ionization-time of flight peptide mass fingerprinting (MALDI-TOF/PMF).
  • When transplanted into nude mice, YDOV-139 cells successfully induced tumor masses in all three animals.
  • In IHC analysis, ER-60 (PDIA3) was significantly overexpressed in both borderline tumors and invasive ovarian cancers (P<0.001).
  • [MeSH-minor] Aged. Animals. Antineoplastic Combined Chemotherapy Protocols / pharmacology. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Carboplatin / administration & dosage. Cell Culture Techniques. Cell Line, Tumor. Female. Gene Expression Regulation, Neoplastic. Humans. Mice. Mice, Inbred BALB C. Mice, Nude. Paclitaxel / administration & dosage. Up-Regulation. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20596667.001).
  • [ISSN] 1791-2423
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; BG3F62OND5 / Carboplatin; EC 5.3.4.1 / Protein Disulfide-Isomerases; EC 5.3.4.1. / PDIA3 protein, human; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


46. Wei HM, Qin SK, Yin XJ, Chen YL: [Therapeutic features of endostar, a modified endostatin, on ascites tumor in mice]. Nan Fang Yi Ke Da Xue Xue Bao; 2010 Jul;30(7):1509-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic features of endostar, a modified endostatin, on ascites tumor in mice].
  • OBJECTIVE: To investigate the effect of endostar in controlling ascites tumor formation in mice.
  • METHODS: Mouse models bearing ascites tumors were established via intraperitoneal injection of H22 and S180 cell lines.
  • The body weight curve of mice was drawn, and the cumulative ascites volume and number of red cells and tumor cells in the malignant ascites were determined.
  • RESULTS: Compared with the control group, the mice receiving daily endostar injection showed obviously lower ascites accumulation and peritoneal capillary permeability (P<0.05) with reduced count of ascites tumor cells and red cells and tumor burden of the abdominal cavity.
  • CONCLUSIONS: Continuous intraperitoneal injection can be the optimal means for endostar administration for treatment of malignant ascites.
  • [MeSH-major] Carcinoma, Ehrlich Tumor / blood supply. Endostatins / administration & dosage. Endostatins / pharmacology
  • [MeSH-minor] Animals. Cell Line, Tumor. Female. Humans. Mice. Mice, Inbred ICR. Neovascularization, Pathologic. Recombinant Proteins / administration & dosage. Recombinant Proteins / pharmacology. Recombinant Proteins / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20650753.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Endostatins; 0 / Recombinant Proteins; 0 / endostar protein
  •  go-up   go-down


47. Tica I, Tica VI, Mihailov C: Rare association of adrenal tumors. Rom J Intern Med; 2007;45(1):107-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare association of adrenal tumors.
  • We present an interesting case because of the surprising association of two adrenal tumors, with a long time lapse between them, with ascites and pleurisy and because of the difficulty of treatment in a patient refusing surgery.
  • She presented at admission cashexia, pallor, signs of left pleural effusion and of ascites, hearts beats and blood pressure within normal limits.
  • Investigations were performed including hormonal tests, ultrasound investigation, hepatic tests, and CT scan but no specific tumour markers.
  • A right adrenal incidentaloma of 21/15 mm - in association with ascites and pleurisy - was found at CT scan.
  • [MeSH-major] Adrenal Gland Neoplasms / complications. Adrenal Gland Neoplasms / diagnosis. Ascites / complications. Pheochromocytoma / complications. Pleurisy / complications

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17966451.001).
  • [ISSN] 1220-4749
  • [Journal-full-title] Romanian journal of internal medicine = Revue roumaine de médecine interne
  • [ISO-abbreviation] Rom J Intern Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


48. Chen P, Hu WM, Wang PH, Suen JH: Recurrent breast cancer presents as a single solid ovarian mass and ascites. Taiwan J Obstet Gynecol; 2006 Dec;45(4):356-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent breast cancer presents as a single solid ovarian mass and ascites.
  • OBJECTIVE: Ovarian malignancy is highly suspected when patients present with an ovarian cystic mass lesion accompanied with ascites.
  • Herein, we report the case of a patient with a left adnexal mass and ascites to emphasize consideration of metastatic ovarian tumors from non-gynecologic organs.
  • CASE REPORT: A 47-year-old woman with a history of right breast infiltrating lobular carcinoma, T3N0M0, grade 3, was treated with modified radical mastectomy and axillary lymph-node dissection in July 2001.
  • Tumor recurrence was noted in December 2003.
  • In March 2006, she experienced poor appetite and abdominal fullness, and was found to have a 12-cm adnexal mass accompanied with ascites.
  • However, metastatic carcinoma of the ovary of breast origin was finally diagnosed.
  • CONCLUSION: In cases of pelvic tumors in patients who have a history of other primary cancers, metastasis should be suspected initially.
  • [MeSH-major] Ascites / etiology. Breast Neoplasms / pathology. Carcinoma / secondary. Ovarian Neoplasms / secondary


49. Schmeding M, Neumann U, Neuhaus P: Colonic metastasis of Klatskin tumor: case report and discussion of the current literature. World J Gastroenterol; 2006 Sep 7;12(33):5393-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colonic metastasis of Klatskin tumor: case report and discussion of the current literature.
  • Abdominal ultrasound indicated enlarged intrahepatic bile ducts, abdominal CT scan and ERC were performed and bile duct carcinoma (Klatskin Type III b) was diagnosed.
  • The tumor was located in the segments 2, 3, 4 and 1 with possible invasion of the left intrahepatic portal vein.
  • A specimen of the ascites present preoperatively displayed no malignant cells.
  • Following laparotomy we found local peritoneal carcinosis in the ligamentum hepatoduodenale with lymphatic nodules that tested positive for cholangiocellular carcinoma in online pathological examination.
  • In the course of further exploration of the abdomen a solid tumor was detected in the sigmoid colon.
  • Histological examination of the resected sigmoid revealed transmural manifestation of a malignant neoplastic process with both a tubular and a solid growth pattern in conformity with metastasis of a Klatskin tumor.
  • Peritoneal carcinosis is a common phenomenon in the dissemination pattern of advanced-stage Klatskin tumors, yet to our knowledge this is the first case of intramural colonic growth following peritoneal metastasis.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Colonic Neoplasms / diagnosis. Colonic Neoplasms / secondary. Klatskin Tumor / pathology

  • Genetic Alliance. consumer health - Klatskin tumor.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1999 Aug;230(2):266-75 [10450742.001]
  • [Cites] Hepatology. 2003 May;37(5):961-9 [12717374.001]
  • [Cites] Semin Oncol. 1988 Apr;15(2):106-15 [2835814.001]
  • [Cites] Ann Surg. 1992 Jan;215(1):31-8 [1309988.001]
  • [Cites] Ann Surg. 1991 Jan;213(1):21-5 [1845927.001]
  • [Cites] Arch Surg. 1995 Mar;130(3):270-6 [7534059.001]
  • [Cites] World J Surg. 1995 Jan-Feb;19(1):83-8 [7740815.001]
  • [Cites] Ann Surg. 1996 Nov;224(5):628-38 [8916878.001]
  • [Cites] Dig Surg. 1999;16(3):209-13 [10436369.001]
  • [Cites] Cancer. 1995 Jan 1;75(1 Suppl):171-90 [8000995.001]
  • (PMID = 16981275.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4088212
  •  go-up   go-down


50. Jakobs TF, Hoffmann RT, Fischer T, Stemmler HJ, Tatsch K, La Fougere C, Murthy R, Reiser MF, Helmberger TK: Radioembolization in patients with hepatic metastases from breast cancer. J Vasc Interv Radiol; 2008 May;19(5):683-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After treatment, the authors assessed tumor response with computed tomography and/or magnetic resonance imaging by using Response Evaluation Criteria in Solid Tumors (RECIST), laboratory and clinical toxicities, and survival.
  • Follow-up at a median of 4.2 months demonstrated partial response, stable disease, and progressive disease in 61%, 35%, and 4% of patients, respectively.
  • With respect to tumor diameters, imaging revealed a maximum and minimum response of -64.8% to +23.6%, respectively (mean, 29.2%; median, 39.7%).
  • The median survival of responders and nonresponders was 23.6 and 5.7 months, respectively, and the median survival of patients with and patients without extrahepatic disease was 9.6 and 16 months.
  • Clinically significant toxicities with the appearance of increasing transaminase level, increasing bilirubin level, nausea and vomiting, gastric ulcers, and ascites occurred in eight of 30 patients.
  • Response to radioembolization in these patients is supported by the decrease in tumor size.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18440456.001).
  • [ISSN] 1051-0443
  • [Journal-full-title] Journal of vascular and interventional radiology : JVIR
  • [ISO-abbreviation] J Vasc Interv Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Yttrium Radioisotopes
  •  go-up   go-down


51. Yu J, Liu H, Lei J, Tan W, Hu X, Zou G: Antitumor activity of chloroform fraction of Scutellaria barbata and its active constituents. Phytother Res; 2007 Sep;21(9):817-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At 60 mg/kg/day, CE-SB significantly inhibited the solid tumor proliferation and increased the life span of ascites tumor bearing mice (p < 0.01).
  • [MeSH-minor] Animals. Cell Line, Tumor / drug effects. Electrophoresis, Agar Gel. Flow Cytometry. Humans. Inhibitory Concentration 50. Male. Medicine, Chinese Traditional. Mice. Mice, Inbred Strains

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17674423.001).
  • [ISSN] 0951-418X
  • [Journal-full-title] Phytotherapy research : PTR
  • [ISO-abbreviation] Phytother Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Plant Extracts
  •  go-up   go-down


52. Samanta S, Pain A, Dutta S, Saxena AK, Shanmugavel M, Pandita RM, Qazi GN, Sanyal U: Antitumor activity of Nitronaphthal-NU, a novel mixed-function agent. J Exp Ther Oncol; 2005;5(1):15-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In vitro screening in four human tumor cell lines namely SNB-78 CNS, HOP-62 Lung, T47D Breast and SiHa - cervix revealed significant cytotoxicity in the former two cell lines much greater than CCNU and comparable to Mitonafide used as standards.
  • In vivo antitumoral potency assessed in the murine ascites tumors Sarcoma-180 (S-180) and Ehrlich ascites carcinoma (EAC) by measuring the increase in median survival times of drug treated (T) over untreated control (C) mice, revealed highly significant (p<0.001) tumor regression effects greater than standards.
  • Life span of mice bearing advanced tumor for 10 days before the drug challenge was also considerably increased.
  • The compound comparable to standards inhibited the synthesis of DNA and RNA in S-1 80 tumor cells.
  • [MeSH-minor] Alkylation. Animals. Cell Line, Tumor. DNA / drug effects. DNA / metabolism. DNA, Neoplasm / biosynthesis. Drug Screening Assays, Antitumor. Drug Synergism. Humans. Imides / therapeutic use. Isoquinolines / therapeutic use. Lomustine / therapeutic use. Mice. Naphthalimides. Neoplasm Transplantation. RNA, Neoplasm / biosynthesis. Sarcoma 180 / metabolism. Thymidine / metabolism. Uridine / metabolism

  • Hazardous Substances Data Bank. LOMUSTINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16416597.001).
  • [ISSN] 1359-4117
  • [Journal-full-title] Journal of experimental therapeutics & oncology
  • [ISO-abbreviation] J. Exp. Ther. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA, Neoplasm; 0 / Imides; 0 / Isoquinolines; 0 / Naphthalenes; 0 / Naphthalimides; 0 / RNA, Neoplasm; 0 / nitronaphthal-NU; 06Q0V17SI9 / mitonafide; 7BRF0Z81KG / Lomustine; 9007-49-2 / DNA; VC2W18DGKR / Thymidine; WHI7HQ7H85 / Uridine
  •  go-up   go-down


53. Grazi GL: Liver resections: complications and survival outcome. Expert Rev Pharmacoecon Outcomes Res; 2007 Jun;7(3):269-79
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Today, liver resection represents one of the most effective therapies in the treatment of defined liver diseases, particularly for hepatocellular carcinomas, liver metastases and tumors originating from the bile ducts.
  • The procedure is still burdened with some postoperative complications, the more characteristic of which are liver insufficiency, biliary leakage and ascites.
  • Several neoplastic diseases, both primitive and secondary, can benefit from this therapy with substantial improvement of long-term survival, and a notable change in the natural history of the disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20528313.001).
  • [ISSN] 1744-8379
  • [Journal-full-title] Expert review of pharmacoeconomics & outcomes research
  • [ISO-abbreviation] Expert Rev Pharmacoecon Outcomes Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


54. Welsch T, Endlich K, Giese T, Büchler MW, Schmidt J: Eps8 is increased in pancreatic cancer and required for dynamic actin-based cell protrusions and intercellular cytoskeletal organization. Cancer Lett; 2007 Oct 8;255(2):205-18
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eps8 levels were higher in cell lines derived from ascites and metastases than in those from primary tumors.
  • Expression correlated positively with the migratory potential of tumor cells.
  • We concluded that Eps8 is increased in pancreatic cancer and correlates with migratory potential and tumor progression in vitro.
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Cell Line, Tumor. Cell Movement / drug effects. Cell Surface Extensions / chemistry. Cell Surface Extensions / metabolism. Cell Surface Extensions / ultrastructure. Cytoskeleton / ultrastructure. Humans. Pancreas / chemistry. Pancreas / ultrastructure. RNA, Small Interfering / pharmacology. Up-Regulation

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17537571.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Actins; 0 / Adaptor Proteins, Signal Transducing; 0 / EPS8 protein, human; 0 / Intracellular Signaling Peptides and Proteins; 0 / RNA, Small Interfering
  •  go-up   go-down


55. Lans TE, van Ramshorst GH, Hermans JJ, den Bakker MA, Tran TC, Kazemier G: Perivascular epithelioid cell tumor of the retroperitoneum in a young woman resulting in an abdominal chyloma. J Gastrointest Surg; 2009 Feb;13(2):389-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perivascular epithelioid cell tumor of the retroperitoneum in a young woman resulting in an abdominal chyloma.
  • Perivascular epithelioid cell tumor (PEComa) is an extremely rare neoplasm which appears to have predominancy for young, frequently Asian, women.
  • These tumors have been reported in various organs under a variety of designations.
  • The postoperative period was complicated by chylous ascites that was initially controlled by a wait-and-see policy with total parenteral nutrition.
  • [MeSH-major] Chylous Ascites / etiology. Perivascular Epithelioid Cell Neoplasms / complications. Perivascular Epithelioid Cell Neoplasms / surgery. Postoperative Complications. Retroperitoneal Neoplasms / complications. Retroperitoneal Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 2003 Aug;56(8):627-8 [12890819.001]
  • [Cites] Kaohsiung J Med Sci. 2005 Jun;21(6):277-81 [16035571.001]
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12):1558-75 [16327428.001]
  • [Cites] Pediatr Blood Cancer. 2005 Aug;45(2):202-6 [15704192.001]
  • [Cites] Histopathology. 2006 Jan;48(1):75-82 [16359539.001]
  • [Cites] APMIS. 2004 Feb;112(2):98-104 [15056225.001]
  • [Cites] J Pediatr Hematol Oncol. 2005 Dec;27(12):681-4 [16344678.001]
  • [Cites] Mod Pathol. 2002 Jan;15(1):87-90 [11796846.001]
  • [Cites] Oncologist. 2005 Sep;10(8):632-5 [16177287.001]
  • [Cites] Hum Pathol. 2006 May;37(5):606-12 [16647959.001]
  • (PMID = 18213505.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


56. Rosanò L, Spinella F, Di Castro V, Decandia S, Nicotra MR, Natali PG, Bagnato A: Endothelin-1 is required during epithelial to mesenchymal transition in ovarian cancer progression. Exp Biol Med (Maywood); 2006 Jun;231(6):1128-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ET-1 and ET(A)R are overexpressed in primary and metastatic ovarian carcinomas, and high levels of ET-1 are detectable in patient ascites, suggesting that ET-1 may promote tumor dissemination.
  • Moreover, in these tumors, engagement of ET(A) receptor by ET-1 triggers tumor growth, survival, angiogenesis, and invasiveness.
  • Therefore, we investigated the role of the ET-1/ET(A)R autocrine axis in promoting epithelial to mesenchymal transition (EMT) in ovarian tumor cells, a key event in cancer metastasis, in which epithelial cells depolarize, disassemble cell-cell contacts, and adopt an invasive phenotype.
  • We found that in 3-D serum-free collagen I gel cultures, HEY and OVCA 433 ovarian carcinoma cells undergo fibroblast-like morphologic changes between 3 and 5 days of ET-1 treatment.
  • Collectively, these findings provide evidence of a critical role for the ET-1/ET(A)R axis during distinct steps of ovarian carcinoma progression, thus underlining this axis as a potential target in the treatment of ovarian cancer.
  • [MeSH-minor] Cell Line, Tumor. Collagen Type I / metabolism. Culture Media, Serum-Free. Disease Progression. Endothelin A Receptor Antagonists. Female. Humans. Neoplasm Invasiveness. Organ Culture Techniques. Receptor, Endothelin A / genetics. Receptor, Endothelin A / metabolism. Time Factors


57. Quinteiro-Filho WM, Righi DA, Palermo-Neto J: Effect of cyhalothrin on Ehrlich tumor growth and macrophage activity in mice. Braz J Med Biol Res; 2009 Oct;42(10):912-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of cyhalothrin on Ehrlich tumor growth and macrophage activity in mice.
  • Macrophages are key elements in cellular immune responses and operate at the tumor-host interface.
  • This study investigated the relationship among cyhalothrin effects on Ehrlich tumor growth, serum corticosterone levels and peritoneal macrophage activity in mice.
  • Cyhalothrin i) increased Ehrlich ascitic tumor growth after ip administration of 5.0 x 106 tumor cells, i.e., ascitic fluid volume (control = 1.97 +/- 0.39 mL and experimental = 2.71 +/- 0.92 mL; P < 0.05), concentration of tumor cells/mL in the ascitic fluid (control = 111.95 +/- 16.73 x 106 and experimental = 144.60 +/- 33.18 x 106; P < 0.05), and total number of tumor cells in the ascitic fluid (control = 226.91 +/- 43.22 x 106 and experimental = 349.40 +/- 106.38 x 106; P < 0.05);.
  • These data provide evidence that cyhalothrin simultaneously alters host resistance to Ehrlich tumor growth, hypothalamic-pituitary-adrenocortical (HPA) axis function, and peritoneal macrophage activity.
  • The results are discussed in terms of data suggesting a link between stress, HPA axis activation and resistance to tumor growth.

  • Hazardous Substances Data Bank. CYHALOTHRIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19784476.001).
  • [ISSN] 1414-431X
  • [Journal-full-title] Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas
  • [ISO-abbreviation] Braz. J. Med. Biol. Res.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Insecticides; 0 / Nitriles; 0 / Pyrethrins; V0V73PEB8M / cyhalothrin; W980KJ009P / Corticosterone
  •  go-up   go-down


58. Valentin L, Ameye L, Testa A, Lécuru F, Bernard JP, Paladini D, Van Huffel S, Timmerman D: Ultrasound characteristics of different types of adnexal malignancies. Gynecol Oncol; 2006 Jul;102(1):41-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To describe ultrasound characteristics of adnexal malignancies, i.e., borderline ovarian tumors, primary invasive ovarian epithelial cancer stage 1, primary invasive ovarian epithelial cancer stages 2-4, rare types of malignancy, and metastatic tumors.
  • RESULTS: Of 1,066 masses, 266 were malignant and are included: 55 ovarian borderline tumors, 144 primary invasive epithelial ovarian cancers (42 stage 1, 102 stages 2-4), 25 rare malignancies, and 42 metastatic tumors.
  • Most (56%) metastatic tumors and most (60%) rare types of tumor were solid and richly vascularized at color Doppler ultrasound examination (on a scale ranging from 1 to 4, color score based on subjective evaluation was 3 or 4 in 88% and 86%, respectively).
  • Borderline ovarian tumors and stage 1 primary invasive ovarian epithelial cancers differed from stages 2-4 primary invasive ovarian epithelial cancers: they were larger (median volume 375 ml and 695 ml vs. 209 ml; P = 0.0213 and 0.0001), a larger proportion contained papillary projections (64% and 67% vs. 41%; P = 0.0072 and 0.0054), they were more often multilocular cysts without solid components (18% and 14% vs. 2%; P < 0.0017 and 0.0204), but they were less often purely solid (5% and 7% vs. 38%; P <or= 0.0001 and 0.0005).
  • With increasing degree of invasiveness - from borderline epithelial ovarian tumors via stage 1 invasive epithelial ovarian tumors to stages 2-4 invasive epithelial ovarian tumors - ascites became more common (9% vs. 31% vs. 61%; P = 0.0082, <0.0001, and 0.0017), and, among tumors with solid components (n = 179), the proportion of tumor consisting of solid tissue increased (median 2%-10%-34%; P = 0.0212, <0.0001, and 0.0003).
  • CONCLUSION: Papillary projections are characteristic of borderline tumors and stage 1 primary invasive epithelial ovarian cancer.
  • A small proportion of solid tissue at ultrasound examination makes a malignant mass more likely to be a borderline tumor or a stage 1 epithelial ovarian cancer than an advanced ovarian cancer, a metastasis, or a rare type of tumor.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16386783.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


59. Tomihara K, Guo M, Shin T, Sun X, Ludwig SM, Brumlik MJ, Zhang B, Curiel TJ, Shin T: Antigen-specific immunity and cross-priming by epithelial ovarian carcinoma-induced CD11b(+)Gr-1(+) cells. J Immunol; 2010 Jun 1;184(11):6151-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antigen-specific immunity and cross-priming by epithelial ovarian carcinoma-induced CD11b(+)Gr-1(+) cells.
  • It is known that, although both systems initially eliminate emerging tumor cells efficiently, tumors eventually escape immune attack by a variety of mechanisms, including differentiation and recruitment of immunosuppressive CD11b(+)Gr-1(+) myeloid suppressor cells into the tumor microenvironment.
  • However, we show that CD11b(+)Gr-1(+) cells found in ascites of epithelial ovarian cancer-bearing mice at advanced stages of disease are immunostimulatory rather than being immunosuppressive.
  • Adoptive transfer of these immunostimulatory CD11b(+)Gr-1(+) cells from ascites of ovarian cancer-bearing mice results in the significant regression of s.c. tumors even without being pulsed with exogenous tumor Ag prior to adoptive transfer.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20427766.001).
  • [ISSN] 1550-6606
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA149669
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens; 0 / Antigens, CD11b; 0 / Gr-1 protein, mouse; 0 / Receptors, Chemokine
  •  go-up   go-down


60. Tomov S, Gorchev G, Khinkova N, Tsingilev D: [Clinical aspects in expression of epidermal growth factor receptors in epithelial ovarian tumors]. Akush Ginekol (Sofiia); 2007;46(4):29-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical aspects in expression of epidermal growth factor receptors in epithelial ovarian tumors].
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma / metabolism. Epithelium / metabolism. Ovarian Neoplasms / metabolism. Receptor, Epidermal Growth Factor / biosynthesis
  • [MeSH-minor] Ascites / etiology. Ascites / metabolism. Ascites / pathology. Data Interpretation, Statistical. Female. Humans. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Predictive Value of Tests. Prognosis. Prospective Studies. Radioligand Assay

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17974192.001).
  • [ISSN] 0324-0959
  • [Journal-full-title] Akusherstvo i ginekologii︠a︡
  • [ISO-abbreviation] Akush Ginekol (Sofiia)
  • [Language] bul
  • [Publication-type] Journal Article
  • [Publication-country] Bulgaria
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


61. Sughayer MA, Zakarneh L, Abu-Shakra R: Collision metastasis of breast and ovarian adenocarcinoma in axillary lymph nodes: a case report and review of the literature. Pathol Oncol Res; 2009 Sep;15(3):423-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite their accepted clinical and genetic association, the incidence of synchronous breast and ovarian carcinoma is rare.
  • Review of the literature revealed eleven cases of metastatic malignant tumors colliding in the same lymph node, none of which had both ovarian and breast carcinoma.
  • Our case was that of a 63 year old woman presenting with a breast lump that was diagnosed as infiltrating ductal carcinoma after a needle biopsy.
  • One month later the patient was found to have malignant ascites, omental carcinomatosis and an ovarian mass.
  • When surgery was done to treat the breast tumor some of the axillary lymph nodes revealed metastases from the breast primary, others metastases from the ovarian primary and one had both tumors in a collision phenomenon.
  • Immunohistochemistry was used to confirm this finding.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1996 Feb;20(2):245-50 [8554115.001]
  • [Cites] Am J Clin Pathol. 1983 Aug;80(2):228-30 [6349326.001]
  • [Cites] Pathol Int. 1996 Oct;46(10):787-90 [8916150.001]
  • [Cites] Int J Urol. 1997 Mar;4(2):222-4 [9179702.001]
  • [Cites] Dis Colon Rectum. 2005 Feb;48(2):384-9 [15812588.001]
  • [Cites] Science. 1994 Oct 7;266(5182):66-71 [7545954.001]
  • [Cites] Arch Pathol Lab Med. 2004 Mar;128(3):318-20 [14987155.001]
  • [Cites] Int Urol Nephrol. 1995;27(6):743-5 [8725040.001]
  • [Cites] Science. 1994 Sep 30;265(5181):2088-90 [8091231.001]
  • [Cites] Arch Pathol Lab Med. 2001 Oct;125(10):1354-7 [11570915.001]
  • [Cites] J Pathol. 1969 Jan;97(1):143-5 [5783628.001]
  • [Cites] Surg Radiol Anat. 1993;15(2):119-23 [7690160.001]
  • (PMID = 19067238.001).
  • [ISSN] 1532-2807
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / CA-125 Antigen; 0 / Carrier Proteins; 0 / Glycoproteins; 0 / PIP protein, human
  • [Number-of-references] 12
  •  go-up   go-down


62. Nanashima A, Abo T, Sumida Y, Takeshita H, Hidaka S, Furukawa K, Sawai T, Yasutake T, Masuda J, Morisaki T, Nagayasu T: Clinicopathological characteristics of patients with hepatocellular carcinoma after hepatectomy: relationship with status of viral hepatitis. J Surg Oncol; 2007 Nov 1;96(6):487-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological characteristics of patients with hepatocellular carcinoma after hepatectomy: relationship with status of viral hepatitis.
  • BACKGROUND AND OBJECTIVES: Viral hepatitis may modulate the status of liver dysfunction, tumor biology, and postoperative course in patients with hepatocellular carcinoma (HCC).
  • The prevalence rates of intrahepatic metastasis, tumor vascular involvement, and low curability in HBCV group were higher than in the other groups.
  • Uncontrolled ascites and hepatic failure were significantly more common in HBCV group than other groups.
  • The disease-free and overall survival rates of non-B-non-C group were better than those of the other groups; both survival rates were the worst in HBCV group than the other groups.
  • CONCLUSIONS: HCC patients with co-infection of HBV and HCV had poorer liver function and more advanced tumors compared with the other groups.
  • [MeSH-major] Carcinoma, Hepatocellular / complications. Carcinoma, Hepatocellular / surgery. Hepatitis, Viral, Human / complications. Liver Neoplasms / complications. Liver Neoplasms / surgery

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17657729.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Hackethal A, Brueggmann D, Turovets M, Bassaly B, Stein A, Gerber EL, Muenstedt K: Removal of enormous bilateral mucinous cystadenomas of the ovaries with abdominal plastic reconstruction. Arch Gynecol Obstet; 2009 Jan;279(1):65-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These tumors are benign and might lead to abdominal distension, if no secondary symptoms occur and patient delay the consultation of physicians.
  • Transabdominal punctions were performed because of suspected ascites.
  • Finally the patient was transferred to the gynecological department after forced diuresis did not reduce the suspected ascites and a CT scan showed large intraabdominal masses.
  • Tumor excision was initiated and final histology revealed bilateral mucinous cystadenoma of the ovaries.
  • DISCUSSION: Huge intraabdominal tumors that almost double a patient's body weight can hardly be malign.
  • Total tumor excision is necessary because the heterogeneous composition requires careful examination by pathologists to rule out borderline tumors and non-invasive carcinomas.
  • After tumor excision an abdominal wall reconstruction might be necessary because of the laxity and redundancy of the skin.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18386030.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


64. Friedli A, Fischer E, Novak-Hofer I, Cohrs S, Ballmer-Hofer K, Schubiger PA, Schibli R, Grünberg J: The soluble form of the cancer-associated L1 cell adhesion molecule is a pro-angiogenic factor. Int J Biochem Cell Biol; 2009 Jul;41(7):1572-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A soluble form of the L1 cell adhesion molecule (sL1) is released from various tumor cells and can be found in serum and ascites fluid of uterine and ovarian carcinoma patients. sL1 is a ligand for several Arg-Gly-Asp (RGD)-binding integrins and can be deposited in the extracellular matrix.
  • We demonstrated that the anti-L1 monoclonal antibody (mAb) chCE7 binds near or to the sixth Ig-like domain of human L1 which contains a single RGD sequence. mAb chCE7 inhibited the RGD-dependent adhesion of ovarian carcinoma cells to sL1 and reversed the sL1-induced proliferation, matrigel invasion and tube formation of bovine aortic endothelial (BAE) cells.
  • A combination of sL1 with vascular endothelial growth factor-A (VEGF-A(165)), which is an important angiogenic inducer in tumors, strongly potentiated VEGF receptor-2 tyrosine phosphorylation in BAE cells.
  • These results indicate an important role of released L1 in tumor angiogenesis and represent a novel function of antibody chCE7 in tumor therapy.
  • [MeSH-minor] Animals. Antibodies, Monoclonal. Cattle. Cell Adhesion / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Chickens. Chorioallantoic Membrane / blood supply. Chorioallantoic Membrane / drug effects. Collagen / metabolism. Drug Combinations. Endothelial Cells / cytology. Endothelial Cells / drug effects. Endothelial Cells / enzymology. Female. Fibronectins / chemistry. Humans. Laminin / metabolism. Oligopeptides / metabolism. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. Protein Structure, Tertiary. Proteoglycans / metabolism. Repetitive Sequences, Amino Acid. Solubility / drug effects. Vascular Endothelial Growth Factor A / pharmacology. Vascular Endothelial Growth Factor Receptor-2 / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19401151.001).
  • [ISSN] 1878-5875
  • [Journal-full-title] The international journal of biochemistry & cell biology
  • [ISO-abbreviation] Int. J. Biochem. Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Angiogenic Proteins; 0 / Antibodies, Monoclonal; 0 / Drug Combinations; 0 / Fibronectins; 0 / Laminin; 0 / Neural Cell Adhesion Molecule L1; 0 / Oligopeptides; 0 / Proteoglycans; 0 / Vascular Endothelial Growth Factor A; 119978-18-6 / matrigel; 9007-34-5 / Collagen; 99896-85-2 / arginyl-glycyl-aspartic acid; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


65. Gwin K, Mariño-Enríquez A, Martel M, Reyes-Múgica M: Sclerosing stromal tumor: an important differential diagnosis of ovarian neoplasms in childhood and adolescence. Pediatr Dev Pathol; 2009 Sep-Oct;12(5):366-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sclerosing stromal tumor: an important differential diagnosis of ovarian neoplasms in childhood and adolescence.
  • Sclerosing stromal tumors are an uncommon type of benign ovarian sex cord-stromal tumor.
  • Although the usual age of presentation is in the 2nd and 3rd decades, sclerosing stromal tumor can occur in adolescence or premenarchal girls.
  • Clinical symptoms include premature menarche, menstrual irregularities, abdominal discomfort, and rarely, ascites.
  • Imaging studies frequently reveal solid or complex cystic adnexal masses with marked vascularity raising concern for germ cell tumors and, especially in the absence of elevated tumor markers, surface epithelial neoplasms.
  • The differential diagnosis of a benign sclerosing stromal tumor is seldom entertained.
  • We stress the importance of being familiar with sclerosing stromal tumors when evaluating ovarian neoplasms in children and adolescents in order to contribute to the appropriate clinical management preventing extensive and unnecessary surgery, and preserving fertility.
  • [MeSH-major] Ovarian Neoplasms / pathology. Sex Cord-Gonadal Stromal Tumors / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19071970.001).
  • [ISSN] 1093-5266
  • [Journal-full-title] Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • [ISO-abbreviation] Pediatr. Dev. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Zhang S, Zhou X, Yu H, Yu Y: Expression of tumor-specific antigen MAGE, GAGE and BAGE in ovarian cancer tissues and cell lines. BMC Cancer; 2010;10:163
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of tumor-specific antigen MAGE, GAGE and BAGE in ovarian cancer tissues and cell lines.
  • BACKGROUND: To observe mRNA expression of tumor-specific antigen MAGE, BAGE and GAGE in epithelial ovarian cancer tissues and cell lines, to explore the relationship between gene expression and diagnosis, treatment and prognosis of ovarian cancer, and to evaluate the feasibility of their gene products as markers, and an immunotherapy target for ovarian cancer.
  • METHODS: mRNA expression of MAGE-1, MAGE-3, GAGE-1/2 and BAGE were determined by reverse transcription polymerase chain reaction (RT-PCR) in 14 cases of normal ovarian tissue, 20 cases of ovarian benign tumor specimens, 41 cases of ovarian cancer specimens, and ovarian cancer cell lines SKOV3, A2780, and COC1.
  • In benign tumors, only the MAGE gene was expressed; the expression rate of this gene in benign tumors was 15% (3/20).
  • Positive expression of MAGE-1 and MAGE-3 was positively correlated with tumor differentiation and the clinical stage of the ovarian cancer.
  • In addition, the positive expression rate of BAGE was significantly higher in ovarian cancer patients with ascites (P < 0.05).
  • The mRNA expression profiles of MAGE, GAGE and BAGE in ovarian carcinoma cell lines SKOV3, A2780 and COC1 varied, but there was at least one gene expressed in each cell line.
  • CONCLUSION: Tumor-specific antigen MAGE, BAGE and GAGE may play a role in the occurrence and development of ovarian cancer.
  • [MeSH-major] Antigens, Neoplasm / genetics. Biomarkers, Tumor / genetics. Cystadenocarcinoma, Serous / genetics. Neoplasm Proteins / genetics. Ovarian Neoplasms / genetics
  • [MeSH-minor] Cell Line, Tumor. Feasibility Studies. Female. Gene Expression Regulation, Neoplastic. Humans. Melanoma-Specific Antigens. Neoplasm Staging. Prognosis. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Tissue Antigens. 2000 Aug;56(2):166-9 [11019919.001]
  • [Cites] Cancer. 2002 Jun 25;96(3):187-93 [12115308.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Aug;17(4):1051-73 [12959191.001]
  • [Cites] Int J Cancer. 1996 Jul 29;67(3):457-60 [8707425.001]
  • [Cites] Cancer Res. 2008 May 15;68(10):3931-40 [18483279.001]
  • [Cites] Nat Rev Cancer. 2005 Aug;5(8):615-25 [16034368.001]
  • [Cites] J Clin Oncol. 2005 Dec 10;23(35):9008-21 [16061912.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Feb 5;105(5):1650-5 [18216244.001]
  • [Cites] J Immunol. 2008 Mar 1;180(5):3585-93 [18292586.001]
  • [Cites] Br J Cancer. 1998 Sep;78(6):816-21 [9743307.001]
  • (PMID = 20423514.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / BAGE protein, human; 0 / Biomarkers, Tumor; 0 / GAGE1 protein, human; 0 / GAGE2A protein, human; 0 / MAGEA1 protein, human; 0 / MAGEA3 protein, human; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC2868811
  •  go-up   go-down


67. Yang TH, Hwang JI, Yang MS, Hung SW, Chan SW, Wang J, Tyan YS: Gastrointestinal stromal tumors: computed tomographic features and prediction of malignant risk from computed tomographic imaging. J Chin Med Assoc; 2007 Sep;70(9):367-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrointestinal stromal tumors: computed tomographic features and prediction of malignant risk from computed tomographic imaging.
  • BACKGROUND: Gastrointestinal stromal tumors (GISTs) are specific, generally Kit (CD117)-positive, mesenchymal tumors of the gastrointestinal tract encompassing a majority of tumors previously considered gastrointestinal smooth muscle tumors.
  • Images were assessed for the size, contour, growth pattern, boundary, degree of enhancement, and necrosis of the tumors.
  • The presence of calcification within the lesions, abdominal lymphadenopathy, ascites, and bowel obstruction were also recorded.
  • In addition, the relationships between computed tomographic features and tumor size were assessed by means of nonparametric univariate analysis with the MannWhitney U test and KruskalWallis test.
  • RESULTS: Both old age and larger tumor size (>or= 5 cm) were statistically significant in the univariate logistic analysis for high-risk malignant tumors (p < 0.25).
  • However, in multivariate logistic regression, only larger tumor size (>or= 5 cm) was found to have final statistical significance for high-risk malignant GISTs (p < 0.05).
  • CONCLUSION: Larger tumor size (>or= 5 cm) was found to have a predictive value with respect to high-risk malignant GISTs.
  • [MeSH-major] Gastrointestinal Stromal Tumors / radiography. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17908650.001).
  • [ISSN] 1726-4901
  • [Journal-full-title] Journal of the Chinese Medical Association : JCMA
  • [ISO-abbreviation] J Chin Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


68. Yamanaka H, Mizushima T, Mikata S, Ito T, Nonaka K, Ide H, Michiura T, Kainuma S, Iwase K: [Peritoneal dissemination from gastrointestinal stromal tumor of small intestine responding completely to imatinib mesylate (STI 571)]. Gan To Kagaku Ryoho; 2005 Dec;32(13):2125-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Peritoneal dissemination from gastrointestinal stromal tumor of small intestine responding completely to imatinib mesylate (STI 571)].
  • The prognosis of metastatic or recurrent GISTs is poor, because these tumors resist chemotherapy and radiotherapy.
  • The abdominal mass was phi3 x 3.5 cm in size with ascites at Douglas, as determined by computed tomography, and was diagnosed as a peritoneal relapse of GIST.
  • After 1 month of treatment with imatinib, reduction of the abdominal tumor began to be recognized on palpation.
  • Computed tomographic scanning at 11 months revealed that the tumor had completely disappeared.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Gastrointestinal Stromal Tumors / drug therapy. Jejunal Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16352942.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


69. Yokoyama Y, Xin B, Shigeto T, Umemoto M, Kasai-Sakamoto A, Futagami M, Tsuchida S, Al-Mulla F, Mizunuma H: Clofibric acid, a peroxisome proliferator-activated receptor alpha ligand, inhibits growth of human ovarian cancer. Mol Cancer Ther; 2007 Apr;6(4):1379-86
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent reports have shown that peroxisome proliferator-activated receptor (PPAR)alpha ligands reduce growth of some types of malignant tumors and prevent carcinogenesis.
  • CA treatment significantly suppressed the growth of OVCAR-3 tumors xenotransplanted s.c. and significantly prolonged the survival of mice with malignant ascites derived from DISS cells as compared with control.
  • CA treatment increased the expression of carbonyl reductase (CR), which promotes the conversion of prostaglandin E(2) (PGE(2)) to PGF(2alpha), in implanted OVCAR-3 tumors as well as cultured cells.
  • CA treatment decreased PGE(2) level as well as vascular endothelial growth factor (VEGF) amount in both of OVCAR-3-tumor and DISS-derived ascites.
  • Reduced microvessel density and induced apoptosis were found in solid OVCAR-3 tumors treated by CA.
  • [MeSH-minor] Alcohol Oxidoreductases / biosynthesis. Animals. Apoptosis / drug effects. Ascites / metabolism. Cell Line, Tumor. Cell Proliferation / drug effects. Dinoprostone / blood. Disease Models, Animal. Down-Regulation / drug effects. Drug Screening Assays, Antitumor. Enzyme Induction / drug effects. Female. Humans. Intramolecular Oxidoreductases / metabolism. Ligands. Mice. Mice, Inbred BALB C. Microsomes / drug effects. Microsomes / enzymology. Peritonitis. Vascular Endothelial Growth Factor A / genetics

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17431116.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticholesteremic Agents; 0 / Ligands; 0 / PPAR alpha; 0 / Vascular Endothelial Growth Factor A; 53PF01Q249 / Clofibric Acid; EC 1.1.- / Alcohol Oxidoreductases; EC 5.3.- / Intramolecular Oxidoreductases; EC 5.3.99.3 / prostaglandin-E synthase; K7Q1JQR04M / Dinoprostone
  •  go-up   go-down


70. Li GY, Liu JZ, Chen SG, Wang CB, Bin Z, Wang LX: Effect of a seashell protein Haishengsu on the immunological function of mice with Ehrlich ascites tumor. Immunopharmacol Immunotoxicol; 2009;31(4):669-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of a seashell protein Haishengsu on the immunological function of mice with Ehrlich ascites tumor.
  • This study was designed to investigate the effect of a seashell protein Haishengsu (HSS) on the immuno logical function in mice with Ehrlich ascites tumor.
  • Ehrlich ascites tumor-bearing mice were divided into three HSS groups (25, 50 and 100 mg/kg, i.v., respectively), cyclophosphamide (10 mg i.p.) and control group.
  • We conclude that HSS has significant immune-modulating effect in mice with Ehrlich ascites tumor.
  • [MeSH-major] Albumins / therapeutic use. Carcinoma, Ehrlich Tumor / drug therapy. Carcinoma, Ehrlich Tumor / immunology. Drugs, Chinese Herbal / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19874239.001).
  • [ISSN] 1532-2513
  • [Journal-full-title] Immunopharmacology and immunotoxicology
  • [ISO-abbreviation] Immunopharmacol Immunotoxicol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Albumins; 0 / Drugs, Chinese Herbal; 0 / haishengsu
  •  go-up   go-down


71. Mousavi AS, Borna S, Moeinoddini S: Estimation of probability of malignancy using a logistic model combining color Doppler ultrasonography, serum CA125 level in women with a pelvic mass. Int J Gynecol Cancer; 2006 Jan-Feb;16 Suppl 1:92-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The variables that were analyzed by the multivariate logistic regression method are as follows: tumor structure, ascites, presence of septum, the peak systolic velocity (PSV), the resistance index (RI), and serum CA125 level.
  • Of the 101 patients qualified for the study, 48 patients were diagnosed with benign (47.5%) and 53 (52.5%) with malignant tumors.
  • Each criterion used alone provides statistically significant discrimination between benign and malignant tumors.
  • Four criteria could be combined in a malignancy score which is calculated using the product of the serum CA125 level (1 if CA125 > or =40 U/mL and 0 if CA125 <40 U/mL), the result of sonography for presence of septum in tumor (1 if there was septum > or =3 mm, 0 if there was no septum or <3 mm), result of Doppler flow imaging as RI (1 if RI < or =0.5 and 0 if RI >0.5) and the PSV (1 if PSV > or =40 cm/s and 0 if PSV <40 cm/s).
  • [MeSH-major] Biomarkers, Tumor / blood. CA-125 Antigen / blood. Pelvic Neoplasms / blood. Pelvic Neoplasms / diagnosis. Ultrasonography, Doppler, Color

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515574.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen
  •  go-up   go-down


72. Dewan MZ, Terunuma H, Toi M, Tanaka Y, Katano H, Deng X, Abe H, Nakasone T, Mori N, Sata T, Yamamoto N: Potential role of natural killer cells in controlling growth and infiltration of AIDS-associated primary effusion lymphoma cells. Cancer Sci; 2006 Dec;97(12):1381-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Natural killer (NK) cells are an important component of the innate immune response against microbial infections and tumors.
  • Direct involvement of NK cells in tumor growth and infiltration has not yet been demonstrated clearly.
  • Primary effusion lymphoma (PEL) cells were able to produce tumors and ascites very efficiently with infiltration of cells in various organs of T-, B- and NK-cell knock-out NOD/SCID/gammac(null) (NOG) mice within 3 weeks.
  • In contrast, PEL cells formed small tumors at inoculated sites in T- and B-cell knock-out NOD/SCID mice with NK-cells while completely failing to infiltrate into various organs.
  • Activated human NK cells inhibited tumor growth and infiltration in NOG mice.
  • Our results suggest that NK cells play an important role in growth and infiltration of PEL cells, and activated NK cells could be a promising immunotherapeutic tool against tumor or virus-infected cells either alone or in combination with conventional therapy.
  • [MeSH-minor] Animals. Cell Proliferation. Cells, Cultured / pathology. Cells, Cultured / transplantation. Cells, Cultured / virology. Disease Models, Animal. Flow Cytometry. Humans. Immunoenzyme Techniques. Lymphocyte Depletion. Lymphocytes, Tumor-Infiltrating. Mice. Mice, Inbred NOD. Mice, SCID. Neoplasms, Experimental / etiology. Neoplasms, Experimental / pathology. Neoplasms, Experimental / therapy


73. Wang L, Ma J, Liu F, Yu Q, Chu G, Perkins AC, Li Y: Expression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significance. Gynecol Oncol; 2007 Jun;105(3):695-702
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: MUC1 is associated with cellular transformation and tumorigenicity and is considered as an important tumor-associated antigen (TAA) for cancer therapy.
  • The objective of this study was to evaluate the patterns of MUC1 expression in primary tumors and metastatic lesions in the advanced stages of epithelial ovarian cancers (EOCs) and correlate the expression with clinicopathological features.
  • Most of the tumors showed moderate to strong intensity staining while normal ovarian tissues only showed weak intensity staining.
  • The overexpression of MUC1 was significantly associated with various progression parameters such as tumor stage, grade, residual disease status and presence of ascites (P<0.05).
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adult. Aged. Amino Acid Sequence. Antibodies, Monoclonal / chemistry. Antibodies, Monoclonal / immunology. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Epithelial Cells / pathology. Female. Humans. Immunohistochemistry. Middle Aged. Molecular Sequence Data. Mucin-1. Paraffin Embedding


74. Timmerman D, Testa AC, Bourne T, Ferrazzi E, Ameye L, Konstantinovic ML, Van Calster B, Collins WP, Vergote I, Van Huffel S, Valentin L, International Ovarian Tumor Analysis Group: Logistic regression model to distinguish between the benign and malignant adnexal mass before surgery: a multicenter study by the International Ovarian Tumor Analysis Group. J Clin Oncol; 2005 Dec 1;23(34):8794-801
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Logistic regression model to distinguish between the benign and malignant adnexal mass before surgery: a multicenter study by the International Ovarian Tumor Analysis Group.
  • PURPOSE: To collect data for the development of a more universally useful logistic regression model to distinguish between a malignant and benign adnexal tumor before surgery.
  • RESULTS: Data from 1,066 patients recruited from nine European centers were included in the analysis; 800 patients (75%) had benign tumors and 266 (25%) had malignant tumors.
  • (1) personal history of ovarian cancer, (2) hormonal therapy, (3) age, (4) maximum diameter of lesion, (5) pain, (6) ascites, (7) blood flow within a solid papillary projection, (8) presence of an entirely solid tumor, (9) maximal diameter of solid component, (10) irregular internal cyst walls, (11) acoustic shadows, and (12) a color score of intratumoral blood flow.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / blood. CA-125 Antigen / blood. Cystadenoma, Mucinous / classification. Cystadenoma, Mucinous / diagnosis. Cystadenoma, Mucinous / surgery. Cystadenoma, Papillary / classification. Cystadenoma, Papillary / diagnosis. Cystadenoma, Papillary / surgery. Cystadenoma, Serous / classification. Cystadenoma, Serous / diagnosis. Cystadenoma, Serous / surgery. Diagnosis, Differential. Female. Humans. Logistic Models. Middle Aged. Multivariate Analysis. Ovarian Cysts / classification. Ovarian Cysts / diagnosis. Ovarian Cysts / surgery. Ovarian Neoplasms / classification. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / surgery. Ovariectomy. Prospective Studies. Reproducibility of Results. Sensitivity and Specificity

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16314639.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen
  •  go-up   go-down


75. Gencer D, Kästle-Larralde N, Pilz LR, Weiss A, Buchheidt D, Hochhaus A, Hofheinz RD: Presentation, treatment, and analysis of prognostic factors of terminally ill patients with gastrointestinal tumors. Onkologie; 2009 Jul;32(7):380-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Presentation, treatment, and analysis of prognostic factors of terminally ill patients with gastrointestinal tumors.
  • BACKGROUND: Few data have been published about terminally ill patients with gastrointestinal tumors treated in palliative care units.
  • In the multivariate Cox regression analysis, 5 parameters were significant: ascites and anorexia, elevated leukocyte count and lactate dehydrogenase activity, as well as decreased albumine levels.
  • After multicenter validation, these factors may help to guide treatment decisions in terminally ill patients with gastrointestinal tumors.

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19556814.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


76. Ba-Ssalamah A, Uffmann M, Bastati N, Schima W: [Diseases of the peritoneum and mesenterium]. Radiologe; 2009 Jul;49(7):637-51; quiz 652-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Peritoneal diseases can be seen in the different imaging modalities either as fluid collections or solid tumors along the ligaments, mesenteries, and spaces of the peritoneal cavity.
  • In this article, a large variety of peritoneal abnormalities such as ascites, peritonitis, intraperitoneal hemorrhage, and both primary and secondary peritoneal tumors are discussed.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Peritoneal Disorders.
  • MedlinePlus Health Information. consumer health - Ultrasound.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Zentralbl Chir. 1991;116(4):287-9 [2042420.001]
  • [Cites] Vet Radiol Ultrasound. 2008 May-Jun;49(3):227-32 [18546776.001]
  • [Cites] AJR Am J Roentgenol. 2004 Jul;183(1):118 [15208123.001]
  • [Cites] Am J Surg Pathol. 1994 Jun;18(6):591-603 [8179074.001]
  • [Cites] Radiographics. 2002 Nov-Dec;22(6):1511-5 [12432120.001]
  • [Cites] Radiology. 2003 Jan;226(1):86-94 [12511673.001]
  • [Cites] AJR Am J Roentgenol. 2004 Jun;182(6):1463-7 [15149991.001]
  • [Cites] Surg Endosc. 2004 Jul;18(7):1067-70 [15156385.001]
  • [Cites] Radiat Med. 2007 Aug 1;25(7):364-7 [17705008.001]
  • [Cites] Radiographics. 2007 Nov-Dec;27(6):1693-703 [18025512.001]
  • [Cites] Radiographics. 2007 Jan-Feb;27(1):129-43 [17235003.001]
  • [Cites] Br J Radiol. 2004 Jan;77(913):71-3 [14988144.001]
  • [Cites] J Trauma. 1995 Apr;38(4):630-3 [7723108.001]
  • [Cites] Int J Gynaecol Obstet. 2006 Jun;93(3):267-8 [16687143.001]
  • [Cites] Abdom Imaging. 1995 Sep-Oct;20(5):414-20 [7580774.001]
  • [Cites] Radiology. 2003 Apr;227(1):46-51 [12615997.001]
  • [Cites] J Clin Ultrasound. 2005 Feb;33(2):76-9 [15674838.001]
  • [Cites] Radiographics. 1992 May;12(3):445-65 [1609137.001]
  • [Cites] Radiographics. 2005 May-Jun;25(3):719-30 [15888621.001]
  • [Cites] Eur J Surg. 2001 Oct;167(10):723-7 [11775722.001]
  • [Cites] Intern Med. 2008;47(1):73-4 [18176011.001]
  • [Cites] Radiol Clin North Am. 1994 Sep;32(5):913-32 [8085004.001]
  • [Cites] Am J Surg Pathol. 1997 Apr;21(4):392-8 [9130985.001]
  • [Cites] Radiology. 1984 Nov;153(2):507-10 [6385111.001]
  • [Cites] Radiology. 1970 Jun;95(3):547-54 [5442658.001]
  • [Cites] JBR-BTR. 2000 Aug;83(4):153-5 [11126783.001]
  • [Cites] Radiology. 1992 Oct;185(1):169-72 [1523302.001]
  • [Cites] Abdom Imaging. 2008 Jan-Feb;33(1):87-93 [17632751.001]
  • [Cites] Radiology. 1970 Jul;96(1):15-22 [5420399.001]
  • [Cites] N Engl J Med. 2008 Jul 17;359(3):293 [18635434.001]
  • [Cites] AJR Am J Roentgenol. 2000 Feb;174(2):427-31 [10658720.001]
  • [Cites] Eur Radiol. 2008 Jan;18(1):18-23 [17701040.001]
  • [Cites] Br J Radiol. 2007 Nov;80(959):872-7 [17875592.001]
  • [Cites] Radiographics. 2000 Nov-Dec;20(6):1525-36; discussion 1536-7 [11112806.001]
  • [Cites] J Emerg Med. 1999 Sep-Oct;17 (5):823-6 [10499696.001]
  • [Cites] AJR Am J Roentgenol. 2006 Mar;186(3):703-17 [16498098.001]
  • [Cites] Radiographics. 1992 Jan;12 (1):59-77 [1734482.001]
  • [Cites] Dig Surg. 2000;17(4):323-8 [11053936.001]
  • [Cites] Abdom Imaging. 2003 Jul-Aug;28(4):505-14 [14580093.001]
  • [Cites] Pediatr Radiol. 2002 Feb;32(2):88-94 [11819071.001]
  • [Cites] Radiographics. 2005 Nov-Dec;25(6):1501-20 [16284131.001]
  • [Cites] Australas Radiol. 2002 Mar;46(1):91-6 [11966596.001]
  • [Cites] Gastroenterology. 2007 Jul;133(1):14, 372 [17631124.001]
  • [Cites] Abdom Imaging. 1995 Mar-Apr;20(2):138-40 [7787717.001]
  • [Cites] J Trauma. 1996 Nov;41(5):815-20 [8913209.001]
  • [Cites] Eur J Radiol. 2006 Aug;59(2):284-8 [16580806.001]
  • [Cites] Abdom Imaging. 2006 Sep-Oct;31(5):549-54 [16465576.001]
  • [Cites] AJR Am J Roentgenol. 1991 Jun;156(6):1185-7 [2028864.001]
  • (PMID = 19224192.001).
  • [ISSN] 1432-2102
  • [Journal-full-title] Der Radiologe
  • [ISO-abbreviation] Radiologe
  • [Language] ger
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 49
  •  go-up   go-down


77. Kamijo Y, Ito C, Nomura M, Sai Y, Miyamoto K: Surfactants influence the distribution of taxanes in peritoneal dissemination tumor-bearing rats. Cancer Lett; 2010 Jan 28;287(2):182-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surfactants influence the distribution of taxanes in peritoneal dissemination tumor-bearing rats.
  • The effects of surfactants on the disposition kinetics of docetaxel and paclitaxel were examined in tumor-bearing rats.
  • Taxol and Taxotere were administered intraperitoneally to AH130 tumor-bearing rats.
  • The AUC(a,0-24h,ascite)/AUC(p,0-24h) ratio of paclitaxel was approximately 3-fold larger than that of docetaxel.
  • Docetaxel concentrations in free and solid tumors in the peritoneal cavity were higher than those of paclitaxel.
  • These results indicated that Taxol scarcely released paclitaxel, while Taxotere easily released docetaxel, enabling its distribution to tumors disseminated in the peritoneal cavity.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacokinetics. Carcinoma, Hepatocellular / metabolism. Glycerol / analogs & derivatives. Liver Neoplasms / pathology. Paclitaxel / pharmacokinetics. Peritoneal Neoplasms / metabolism. Polysorbates / pharmacology. Surface-Active Agents / pharmacology. Taxoids / pharmacokinetics
  • [MeSH-minor] Animals. Area Under Curve. Ascites / metabolism. Biological Transport. Cell Line, Tumor. Female. Injections, Intraperitoneal. Rats. Tissue Distribution

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. GLYCERIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19608331.001).
  • [ISSN] 1872-7980
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Polysorbates; 0 / Surface-Active Agents; 0 / Taxoids; 15H5577CQD / docetaxel; 6D4M1DAL6O / cremophor EL; P88XT4IS4D / Paclitaxel; PDC6A3C0OX / Glycerol
  •  go-up   go-down


78. Modesitt SC, Parsons SJ: In vitro and in vivo histone deacetylase inhibitor therapy with vorinostat and paclitaxel in ovarian cancer models: does timing matter? Gynecol Oncol; 2010 Nov;119(2):351-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endpoints were survival, ascites and tumor weight.
  • CONCLUSIONS: The efficacy of the combination and sequence of vorinostat and paclitaxel administration was cell line dependent and suggests that responses vary based on tumor specific characteristics.
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cell Line, Tumor. Cyclin B / metabolism. Drug Synergism. Female. Histone Deacetylases / metabolism. Humans. Mice. Mice, Nude. Xenograft Model Antitumor Assays. bcl-2-Associated X Protein / metabolism

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Vorinostat .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20673975.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BAX protein, human; 0 / Cyclin B; 0 / Histone Deacetylase Inhibitors; 0 / Hydroxamic Acids; 0 / bcl-2-Associated X Protein; 58IFB293JI / vorinostat; EC 3.5.1.98 / Histone Deacetylases; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


79. Yang HJ, Kim TH, Park MK, Lim CH, Lee KH, Kim CW, Han SW, Kim JA: [A case of primary extragastrointestinal stromal tumor presenting as peritoneal dissemination]. Korean J Gastroenterol; 2010 Nov;56(5):319-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of primary extragastrointestinal stromal tumor presenting as peritoneal dissemination].
  • Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract, but also occurs at a lower frequency in extra-gastrointestinal regions such as omentum, mesentery, retroperitoneum and undefined abdominal sites.
  • This tumor is called extragastrointestinal stromal tumor (EGIST).
  • EGIST is mostly diagnosed as a cystic mass, but rarely occurs as a disseminated abdominal tumor.
  • Abdominal CT showed diffuse peritoneal thickening with a large amount of ascites, but no definite mass lesion.
  • Laparoscopic biopsy was performed and histologic findings showed tumor composed of epithelioid cells.
  • In the results of immunohistochemical stains, the tumor showed positive reactivity with CD117 (c-kit), CD34, vimentin and actin, but negative reactivity with desmin and S-100 protein.
  • [MeSH-major] Gastrointestinal Stromal Tumors / diagnosis. Peritoneal Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21099240.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Actins; 0 / Antigens, CD34; 0 / Vimentin; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


80. Günther T: Na+/Mg2+ antiport in non-erythrocyte vertebrate cells. Magnes Res; 2007 Jun;20(2):89-99
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Experiments, results and conclusions on Na+/Mg2, antiport in lymphocytes, HL60 cells, Ehrlich ascites tumor cells, platelets, pancreatic acinar cells, sublingual acini, hepatocytes, ruminal epithelial cells, kidney cells, smooth muscle cells, heart muscle cells and skeletal muscle cells were reviewed.
  • [MeSH-minor] Animals. Biological Transport / physiology. Cell Line, Tumor. Cells, Cultured. HL-60 Cells. Homeostasis / physiology. Humans

  • Hazardous Substances Data Bank. MAGNESIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. SODIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18062583.001).
  • [ISSN] 0953-1424
  • [Journal-full-title] Magnesium research
  • [ISO-abbreviation] Magnes Res
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiporters; 9NEZ333N27 / Sodium; I38ZP9992A / Magnesium
  • [Number-of-references] 67
  •  go-up   go-down


81. Chen S, Chen A, Huang C: Establishment of lymphangioma model and a study on the promoting effect of murine melanoma cell B16-F1 on the lymphangiogenesis in vitro. J Huazhong Univ Sci Technolog Med Sci; 2007 Dec;27(6):733-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To establish an animal model of benign lymphangiomas of C57BL/6 mouse in vitro and to observe the effect of mouse ascites melanoma cell B16-F1 on the lymphangiogenesis, 16 C57BL/6 mice aged 8 weeks were given two intraperitoneal injections of incomplete Freund's adjuvant at a 15-day interval.
  • Our results showed that white solid tumor masses developed in peritoneal cavity after the induction.
  • The tumors were confirmed to be lymphangioma by gross and histological examination.
  • The tumor cells expressed both VEGF-C and Flt-4.
  • [MeSH-major] Disease Models, Animal. Lymphangiogenesis / physiology. Lymphangioma. Melanoma / pathology
  • [MeSH-minor] Animals. Cell Line, Tumor. Female. Male. Melanoma, Experimental / pathology. Mice. Mice, Inbred C57BL. Neoplasm Transplantation. Vascular Endothelial Growth Factor C / metabolism. Vascular Endothelial Growth Factor Receptor-3 / metabolism

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2253-9 [12114428.001]
  • [Cites] Lancet Oncol. 2002 Jan;3(1):44-52 [11905605.001]
  • [Cites] Cell Tissue Res. 1999 Jul;297(1):1-11 [10398878.001]
  • [Cites] Med Care. 1999 Jun;37(6):601-14 [10386572.001]
  • [Cites] Nat Med. 2001 Feb;7(2):192-8 [11175850.001]
  • [Cites] Pathol Int. 2002 May-Jun;52(5-6):331-9 [12100515.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3):462-8 [11297234.001]
  • [Cites] Microsc Res Tech. 2001 Oct 15;55(2):108-21 [11596156.001]
  • [Cites] Physiol Rev. 2002 Jul;82(3):673-700 [12087132.001]
  • [Cites] Int J Cancer. 2000 Jan 20;89(1):69-73 [10719733.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1786-90 [11280723.001]
  • (PMID = 18231756.001).
  • [ISSN] 1672-0733
  • [Journal-full-title] Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban
  • [ISO-abbreviation] J. Huazhong Univ. Sci. Technol. Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor C; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-3
  •  go-up   go-down


82. Pourgholami MH, Yan Cai Z, Lu Y, Wang L, Morris DL: Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice. Clin Cancer Res; 2006 Mar 15;12(6):1928-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice.
  • PURPOSE: Angiogenesis and vessel hyperpermeability are the two factors leading to the formation of ascites.
  • Vascular endothelial growth factor (VEGF) plays a pivotal role in malignant ascites formation.
  • The present study was designed to find out if albendazole can suppress ascites formation in ascites-producing peritoneal carcinomatosis.
  • EXPERIMENTAL DESIGN: Female nude mice bearing peritoneal tumors of human ovarian cancer cells (OVCAR-3) were treated with albendazole.
  • Following i.p. inoculation and ascites development, mice were given i.p. albendazole (150 mg/kg) or the vehicle x 3 weekly for 4 weeks.
  • RESULTS: Whereas vehicle-treated mice developed overt ascites requiring repeated aspiration, ascites formation in the albendazole-treated mice was markedly suppressed.
  • Suppressed ascites production and reduced tumor vascularity observed was a result of dramatic reduction in tumor VEGF production as revealed by profoundly lower VEGF ascites fluid and plasma levels.
  • Examination of floating tumor cells collected from the peritoneal wash revealed profound down-regulation of VEGF mRNA in albendazole-treated mice.
  • CONCLUSIONS: These findings suggest for the first time that in nude mice bearing OVCAR-3 peritoneal tumors, by inhibiting VEGF production, albendazole abolishes tumor angiogenesis and ascites formation.
  • [MeSH-major] Albendazole / pharmacology. Ascites / prevention & control. Ovarian Neoplasms / drug therapy. Vascular Endothelial Growth Factor A / antagonists & inhibitors. Xenograft Model Antitumor Assays
  • [MeSH-minor] Animals. CA-125 Antigen / analysis. Cell Line, Tumor. Cell Proliferation / drug effects. Female. Gene Expression / drug effects. Humans. Injections, Intraperitoneal. Mice. Mice, Inbred BALB C. Mice, Nude. Neovascularization, Pathologic / pathology. Neovascularization, Pathologic / prevention & control. Protein Isoforms / antagonists & inhibitors. Protein Isoforms / genetics. Protein Isoforms / secretion. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ALBENDAZOLE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16551879.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-125 Antigen; 0 / Protein Isoforms; 0 / RNA, Messenger; 0 / Vascular Endothelial Growth Factor A; F4216019LN / Albendazole
  •  go-up   go-down


83. Takayasu H, Kitano Y, Kuroda T, Morikawa N, Tanaka H, Fujino A, Muto M, Nosaka S, Tsutsumi S, Hayashi S, Sago H: Successful management of a large fetal mediastinal teratoma complicated by hydrops fetalis. J Pediatr Surg; 2010 Dec;45(12):e21-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This report describes a case of fetal mediastinal teratoma complicated by hydrops fetalis managed successfully by aspiration of the tumor cyst fluid.
  • Fetal mediastinal teratomas are rare tumors that cause hydrops fetalis or fetal demise in the prenatal period and respiratory distress in the neonatal period.
  • The hydrops resolved after fetal aspiration of the tumor cyst fluid.
  • The infant was born without respiratory distress, and tumor resection was performed at the age of 30 days.
  • [MeSH-minor] Adult. Amniocentesis. Ascites / embryology. Edema / embryology. Female. Humans. Infant, Newborn. Magnetic Resonance Imaging. Male. Polyhydramnios / etiology. Pregnancy. Ultrasonography, Prenatal

  • Genetic Alliance. consumer health - Hydrops fetalis.
  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 21129526.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Li Y, Li Y, Niu X, Jie L, Shang X, Guo J, Li Q: Synthesis and antitumor activity of a new mixed-ligand complex di-n-butyl-(4-chlorobenzohydroxamato)tin(IV) chloride. J Inorg Biochem; 2008 Sep;102(9):1731-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synthesis and antitumor activity of a new mixed-ligand complex di-n-butyl-(4-chlorobenzohydroxamato)tin(IV) chloride.
  • Reaction of di-n-butyltin(IV) dichloride with 4-chlorobenzohydroxamic acid at 1:1 ratio yielded a new mixed-ligand diorganotin(IV) complex, di-n-butyl-(4-chlorobenzohydroxamato)tin(IV) chloride(DBDCT).
  • DBDCT exhibited strong in vitro cytotoxic activity toward human immature granulocyte leukemia (HL-60), human salivary-gland carcinoma (SGC-7901), human henrietta carcinoma (Hela) and human urinary bladder (T24) cell lines which, in some cases, were equal to, or even higher than those of cis-dichlorodiammineplatinum(II) (cisplatin, DDP), the widely clinically used drug.
  • The further in vivo antitumor tests of DBDCT towards the transplantation tumor models of sarcoma carcinoma (S(180)), hepatocellular carcinoma (H(22)) and Ehrlich's ascites carcinoma (EAC) on mice were carried out via injection intraperitoneally with cisplatin as positive contrast drug.
  • The results showed that DBDCT displayed in vivo antitumor activity against the hepatocellular carcinoma H(22) and sarcoma carcinoma S(180) which were close to those of cisplatin, meanwhile, the survival-extending rates at middle dose and high dose on mice Ehrlich's ascites tumor EAC were higher than those of cisplatin, and there was a good dose-effect relationship.
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Proliferation / drug effects. Cell Survival / drug effects. Crystallography, X-Ray. HL-60 Cells. HeLa Cells. Humans. Magnetic Resonance Spectroscopy. Mice. Molecular Structure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18573534.001).
  • [ISSN] 1873-3344
  • [Journal-full-title] Journal of inorganic biochemistry
  • [ISO-abbreviation] J. Inorg. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organotin Compounds
  •  go-up   go-down


85. Hellstrom I, Raycraft J, Kanan S, Sardesai NY, Verch T, Yang Y, Hellstrom KE: Mesothelin variant 1 is released from tumor cells as a diagnostic marker. Cancer Epidemiol Biomarkers Prev; 2006 May;15(5):1014-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesothelin variant 1 is released from tumor cells as a diagnostic marker.
  • According to flow cytometry, the molecule that is most frequently expressed at the surface of cells from ovarian carcinomas and certain other tumors is mesothelin variant 1.
  • Similarly, SMRP released into ascites from a patient with ovarian carcinoma was shown to have a molecular weight of approximately 40 kDa and, according to sequencing, to be variant 1.
  • [MeSH-major] Antigens, Neoplasm / blood. Biomarkers, Tumor / blood. Membrane Glycoproteins / blood. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Amino Acid Sequence. Animals. Antibodies, Monoclonal. Cloning, Molecular. Enzyme-Linked Immunosorbent Assay. Female. Flow Cytometry. GPI-Linked Proteins. Mice. Mice, Inbred BALB C. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Epidemiol Biomarkers Prev. 2006 Sep;15(9):1751 [16985043.001]
  • (PMID = 16702385.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA083636; United States / NCI NIH HHS / CA / CA 85780
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin
  •  go-up   go-down


86. McElroy MK, Kaushal S, Tran Cao HS, Moossa AR, Talamini MA, Hoffman RM, Bouvet M: Upregulation of thrombospondin-1 and angiogenesis in an aggressive human pancreatic cancer cell line selected for high metastasis. Mol Cancer Ther; 2009 Jul;8(7):1779-86
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As in many other solid tumors, angiogenesis is critical to the growth and metastasis of this cancer.
  • Through serial in vivo passages in mice, we have developed a highly aggressive variant of human pancreatic cancer cell line XPA-1 which shows more rapid primary tumor growth, faster time to metastasis, and more rapid lethality than the parental cell line.
  • The high-metastatic variant developed a much denser tumor vasculature early during growth within the pancreas.
  • These findings have important implications for the treatment of metastatic disease.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Pancreatic cancer 1.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Invest New Drugs. 1999;17(4):343-59 [10759402.001]
  • [Cites] Br J Cancer. 2008 Aug 19;99(4):622-31 [18665180.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2000;7(5):489-95 [11180876.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2002 Aug 1;22(8):1286-92 [12171789.001]
  • [Cites] Cancer Lett. 2003 Feb 10;190(1):105-12 [12536083.001]
  • [Cites] J Biol Chem. 1978 Dec 10;253(23):8609-16 [101549.001]
  • [Cites] J Invest Dermatol. 1987 Dec;89(6):551-4 [3680981.001]
  • [Cites] Cancer Res. 1993 Nov 1;53(21):5289-96 [7693336.001]
  • [Cites] J Cell Biol. 1994 Jan;124(1-2):183-93 [7507491.001]
  • [Cites] Pancreas. 1995 Nov;11(4):345-9 [8532650.001]
  • [Cites] Cancer Res. 1997 May 15;57(10):2042-7 [9158003.001]
  • [Cites] Exp Cell Res. 1997 Sep 15;235(2):403-12 [9299165.001]
  • [Cites] J Am Coll Surg. 1999 Jul;189(1):1-7 [10401733.001]
  • [Cites] Drugs. 1999 Jul;58(1):17-38 [10439927.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5352-7 [15958583.001]
  • [Cites] Nat Rev Cancer. 2005 Oct;5(10):796-806 [16195751.001]
  • [Cites] J Surg Res. 2006 May 15;132(2):164-9 [16500746.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Cancer Control. 2007 Jul;14(3):285-94 [17615535.001]
  • [Cites] Microvasc Res. 2007 Sep-Nov;74(2-3):72-84 [17560615.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Jun 27;371(2):215-9 [18433719.001]
  • [Cites] Cancer Metastasis Rev. 2000;19(1-2):87-92 [11191069.001]
  • (PMID = 19584238.001).
  • [ISSN] 1538-8514
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / T32 CA121938; United States / NCI NIH HHS / CA / CA103563; United States / NCI NIH HHS / CA / R43 CA103563; United States / NCI NIH HHS / CA / R44 CA103563; United States / NCI NIH HHS / CA / R33 CA109949; United States / NCI NIH HHS / CA / R01 CA142669; United States / NCI NIH HHS / CA / R01 CA132971; United States / NCI NIH HHS / CA / R21 CA109949; United States / NCI NIH HHS / CA / CA109949-03; United States / NCI NIH HHS / CA / R21 CA135435
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Thrombospondin 1
  • [Other-IDs] NLM/ NIHMS119605; NLM/ PMC3487474
  •  go-up   go-down


87. Bige O, Demir A, Koyuncuoglu M, Secil M, Ulukus C, Saygili U: Collision tumor: serous cystadenocarcinoma and dermoid cyst in the same ovary. Arch Gynecol Obstet; 2009 May;279(5):767-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collision tumor: serous cystadenocarcinoma and dermoid cyst in the same ovary.
  • INTRODUCTION: Collision tumor means the coexistence of two adjacent, but histologically distinct tumors without histologic admixture in the same tissue or organ.
  • Collision tumors involving ovaries are extremely rare.
  • CASE: We present a case of 45-year-old parous woman with a left dermoid cyst, with unusual imaging findings, massive ascites and peritoneal carcinomatosis.
  • The histopathology revealed a collision tumor consisting of an invasive serous cystadenocarcinoma and a dermoid cyst.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18818939.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


88. Zhao XY, Huang HF, Lian LJ, Lang JH: Ovarian cancer in pregnancy: a clinicopathologic analysis of 22 cases and review of the literature. Int J Gynecol Cancer; 2006 Jan-Feb;16(1):8-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The incidence of ovarian carcinoma complicating pregnancy in the series was 0.073/1000 pregnancies.
  • Nine (40.9%) were found with ovarian malignant germ cell tumors, six (27.3%) with low malignant potential tumors, five (22.7%) with invasive epithelial tumors, and two (9.1%) with sex cord stromal tumors.
  • Ascites presenting at diagnosis implies advanced disease and gloomy prognosis.
  • Management depends on histology of the tumor, stage of the tumor, and the term of the pregnancy.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445603.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 44
  •  go-up   go-down


89. Cheng WF, Hung CF, Chai CY, Chen CA, Lee CN, Su YN, Tseng WY, Hsieh CY, Shih IeM, Wang TL, Wu TC: Generation and characterization of an ascitogenic mesothelin-expressing tumor model. Cancer; 2007 Jul 15;110(2):420-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Generation and characterization of an ascitogenic mesothelin-expressing tumor model.
  • BACKGROUND: Intraperitoneal tumors expressing high amounts of mesothelin such as malignant mesothelioma and ovarian cancers tend to develop ascites and result in significant morbidity and mortality in the patient.
  • A suitable preclinical intraperitoneal model will assist in the illustration of the mechanisms of molecular oncogenesis and facilitate in addressing issues related to early screening, diagnosis, and therapy for intraperitoneal tumors.
  • METHODS: In the current study, an ascitogenic malignant tumor model (WF-3) was created.
  • In addition, the in vivo tumorgenicity of WF-3 and WF-0 was determined using intraperitoneal injection of the tumor cells.
  • Furthermore, the mesothelin levels in serum and ascites were used to correlate with tumor load of WF-3 in tumor challenged mice.
  • RESULTS: The WF-3 tumor cells demonstrated relatively high proliferation and migration rates compared with the parental cell line, WF-0.
  • The tumors from the WF-3 but not WF-0 were capable of forming ascites and peritoneal-based tumors after tumor challenge.
  • The WF-3 tumor model was also capable of implanting into multiple organs including the diaphragm, intestines, and peritoneal wall.
  • Furthermore, the WF-3 tumor expressed high levels of mesothelin, which is commonly observed in the majority of ovarian cancers, pancreatic cancer, and malignant mesothelioma.
  • In addition, the authors found that the serum and ascites mesothelin levels correlated with tumor loads in tumor-challenged mice.
  • CONCLUSIONS: The data indicate that the WF-3 murine tumor model may potentially serve as a good model for understanding the molecular oncogenesis of peritoneal tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 1992 Dec 2;52(6):881-6 [1459729.001]
  • [Cites] J Virol. 1991 Jan;65(1):473-8 [1845902.001]
  • [Cites] Clin Cancer Res. 1998 Oct;4(10):2455-61 [9796978.001]
  • [Cites] Semin Oncol. 1999 Feb;26(1 Suppl 1):2-7 [10071968.001]
  • [Cites] Microvasc Res. 1999 May;57(3):357-62 [10329263.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11531-6 [10500211.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):827-31 [16467095.001]
  • [Cites] Semin Oncol. 2006 Apr;33(2 Suppl 6):S3-11 [16716797.001]
  • [Cites] Semin Oncol. 2006 Apr;33(2 Suppl 6):S12-6 [16716798.001]
  • [Cites] Obstet Gynecol. 2006 Jun;107(6):1399-410 [16738170.001]
  • [Cites] CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33 [10735013.001]
  • [Cites] Carcinogenesis. 2000 Apr;21(4):585-91 [10753190.001]
  • [Cites] Gastroenterology. 2000 Jul;119(1):211-9 [10889171.001]
  • [Cites] J Immunol. 2001 Mar 1;166(5):3240-7 [11207278.001]
  • [Cites] J Immunol. 2001 May 15;166(10):6218-26 [11342644.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):3862-8 [11751476.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1):41-50 [11836668.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1):82-96 [11836673.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):2295-309 [12466143.001]
  • [Cites] Lancet. 2003 Nov 15;362(9396):1612-6 [14630441.001]
  • [Cites] Cancer Res. 2004 Mar 1;64(5):1655-63 [14996724.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):3937-42 [15217923.001]
  • [Cites] Nat Med. 2004 Sep;10(9):950-8 [15334073.001]
  • [Cites] Am J Pathol. 1998 Oct;153(4):1249-56 [9777956.001]
  • (PMID = 17559144.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U19 CA113341; United States / NCI NIH HHS / CA / 1U19 CA113341-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin
  • [Other-IDs] NLM/ NIHMS321537; NLM/ PMC3181493
  •  go-up   go-down


90. Jiang L, Siu MK, Wong OG, Tam KF, Lam EW, Ngan HY, Le XF, Wong ES, Chan HY, Cheung AN: Overexpression of proto-oncogene FBI-1 activates membrane type 1-matrix metalloproteinase in association with adverse outcome in ovarian cancers. Mol Cancer; 2010;9:318
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent evidence suggests that FBI-1 is expressed at high levels in a subset of human lymphomas and some epithelial solid tumors.
  • Significantly higher FBI-1 protein and mRNA expression levels were demonstrated in ovarian cancers samples and cell lines compared with borderline tumors and benign cystadenomas.
  • Moreover, higher FBI-1 expression was found in metastatic foci (P = 0.036) and malignant ascites (P = 0.021), and was significantly associated with advanced stage (P = 0.012), shorter overall survival (P = 0.032) and disease-free survival (P = 0.016).
  • In vitro, overexpressed FBI-1 significantly enhanced cell migration and invasion both in OVCA 420 and SKOV-3 ovarian carcinoma cells, irrespective of p53 status, accompanied with elevated expression of MT1-MMP, but not MMP-2 or TIMP-2.
  • [MeSH-minor] Adult. Aged. Blotting, Western. Cell Line. Cell Line, Tumor. Cell Movement / genetics. Cell Movement / physiology. Cell Proliferation. Chromatin Immunoprecipitation. Female. Humans. Immunohistochemistry. In Vitro Techniques. Middle Aged. Polymerase Chain Reaction. Protein Binding. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2008 Oct;173(4):1165-72 [18772339.001]
  • [Cites] Int J Biochem Cell Biol. 2008;40(6-7):1362-78 [18258475.001]
  • [Cites] FEBS Lett. 2008 Oct 15;582(23-24):3415-22 [18789327.001]
  • [Cites] J Biol Chem. 2008 Nov 28;283(48):33199-210 [18801742.001]
  • [Cites] Gynecol Oncol. 2009 Feb;112(2):319-24 [18976802.001]
  • [Cites] Carcinogenesis. 2009 Jan;30(1):131-40 [19028702.001]
  • [Cites] Nephrol Dial Transplant. 2009 Mar;24(3):735-42 [18927121.001]
  • [Cites] J Biol Chem. 2009 May 8;284(19):12633-44 [19244234.001]
  • [Cites] J Biol Chem. 2009 May 8;284(19):12727-34 [19286653.001]
  • [Cites] Cancer Lett. 2009 Aug 28;281(2):151-61 [19307055.001]
  • [Cites] J Cell Sci. 2009 Sep 1;122(Pt 17):3015-24 [19692588.001]
  • [Cites] Cancer Res. 2009 Sep 1;69(17):7121-9 [19706774.001]
  • [Cites] Dev Cell. 2009 Oct;17(4):527-40 [19853566.001]
  • [Cites] Neoplasia. 2010 Feb;12(2):161-72 [20126474.001]
  • [Cites] Endocr Rev. 2001 Apr;22(2):255-88 [11294827.001]
  • [Cites] Gene. 2000 Jan 25;242(1-2):75-86 [10721699.001]
  • [Cites] Biochim Biophys Acta. 2010 Jan;1803(1):142-50 [19409422.001]
  • [Cites] Exp Cell Res. 2002 Jan 15;272(2):109-18 [11777335.001]
  • [Cites] Cancer Res. 2002 Oct 1;62(19):5523-7 [12359763.001]
  • [Cites] J Biol Chem. 2004 Mar 19;279(12):11711-8 [14701838.001]
  • [Cites] J Clin Pathol. 2004 Jun;57(6):577-84 [15166260.001]
  • [Cites] J Biol Chem. 1995 Mar 10;270(10):5331-8 [7890645.001]
  • [Cites] Mol Cell Biol. 1997 Jul;17(7):3786-98 [9199312.001]
  • [Cites] Int J Cancer. 1997 Jun 20;74(3):316-21 [9221811.001]
  • [Cites] Hum Pathol. 1998 Feb;29(2):155-65 [9490275.001]
  • [Cites] Blood. 1999 May 15;93(10):3379-90 [10233890.001]
  • [Cites] J Biol Chem. 1999 Aug 6;274(32):22679-85 [10428849.001]
  • [Cites] Nature. 2005 Jan 20;433(7023):278-85 [15662416.001]
  • [Cites] Oncogene. 2005 Feb 3;24(6):1043-52 [15592504.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):355-66 [15864277.001]
  • [Cites] J Biol Chem. 2005 Jul 29;280(30):27783-91 [15917220.001]
  • [Cites] Cancer Res. 2005 Oct 1;65(19):8575-8 [16204018.001]
  • [Cites] Hum Mutat. 2006 Jan;27(1):14-20 [16278824.001]
  • [Cites] Cancer Metastasis Rev. 2006 Mar;25(1):87-98 [16680575.001]
  • [Cites] Semin Oncol. 2006 Apr;33(2 Suppl 6):S3-11 [16716797.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Dec 8;351(1):1-6 [17052694.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] J Biol Chem. 2007 Feb 16;282(7):4924-31 [17158885.001]
  • [Cites] Virchows Arch. 2007 Apr;450(4):387-95 [17377809.001]
  • [Cites] Science. 2007 May 11;316(5826):860-6 [17495164.001]
  • [Cites] Neoplasia. 2007 May;9(5):406-17 [17534446.001]
  • [Cites] J Pathol. 2007 Nov;213(3):294-302 [17907153.001]
  • [Cites] J Biol Chem. 2008 Oct 24;283(43):29341-54 [18682402.001]
  • (PMID = 21176152.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Transcription Factors; 0 / ZBTB7A protein, human; EC 3.4.24.80 / Matrix Metalloproteinase 14
  • [Other-IDs] NLM/ PMC3022670
  •  go-up   go-down


91. Laviolette LA, Garson K, Macdonald EA, Senterman MK, Courville K, Crane CA, Vanderhyden BC: 17beta-estradiol accelerates tumor onset and decreases survival in a transgenic mouse model of ovarian cancer. Endocrinology; 2010 Mar;151(3):929-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 17beta-estradiol accelerates tumor onset and decreases survival in a transgenic mouse model of ovarian cancer.
  • Epidemiological studies have suggested that the female steroid hormones are involved in ovarian carcinogenesis and that women who use hormone replacement therapy are at increased risk of developing the disease.
  • After targeted induction of the oncogene in the OSE, mice develop poorly differentiated ovarian tumors, tumor dissemination to tissues within the abdominal cavity, and a subset develops hemorrhagic ascites.
  • Treatment with P(4) had no impact on the disease, but E(2) altered the pathophysiology, resulting in an earlier onset of tumors, decreased overall survival time, and a distinctive papillary histology.


92. Kong D, Nishino N, Shibusawa M, Kusano M: Establishment and characterization of human pancreatic adenocarcinoma cell line in tissue culture and the nude mouse. Tissue Cell; 2007 Aug;39(4):217-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We established a human pancreatic carcinoma cell line, designated SPH, from cancerous ascites of a 57-year-old male patient with ductal adenocarcinoma of the pancreas.
  • The cells produced CA19-9, SPan-1, and DUPAN-2 in the conditioned medium and formed tumors in nude mice, the histology of which was similar to that of the primary tumor.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / pathology. Disease Models, Animal. Pancreatic Neoplasms / pathology. Tumor Cells, Cultured / pathology
  • [MeSH-minor] Animals. Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. CA-19-9 Antigen / metabolism. Humans. Karyotyping. Male. Mice. Mice, Nude. Middle Aged. Neoplasm Invasiveness. Neoplasm Transplantation

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17560620.001).
  • [ISSN] 0040-8166
  • [Journal-full-title] Tissue & cell
  • [ISO-abbreviation] Tissue Cell
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0 / DU-PAN-2 antigen, human; 0 / pancreatic associated antigen, SPan-1
  •  go-up   go-down


93. Yadav AK, Mishra P, Jain S, Mishra P, Mishra AK, Agrawal GP: Preparation and characterization of HA-PEG-PCL intelligent core-corona nanoparticles for delivery of doxorubicin. J Drug Target; 2008 Jul;16(6):464-78
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The objective of the present study was to synthesize core-corona nanoparticles of doxorubicin (DOX) using hyaluronic acid-polyethyleneglycol-polycaprolactone (HA-PEG-PCL) copolymer for tumor targeting.
  • The tissue distribution study and tumor growth inhibition were performed after intravenous injection of nanoparticles in Ehrlich ascites tumor (EAT)-bearing mice.
  • The nanoparticles of HA-PEG-PCL copolymer accomplishes efficient delivery of DOX in EAT tumor when compared with the MPEG-PCL nanoparticles by the process of receptor-mediated endocytosis, as well as enhanced permeability and retention effect.
  • [MeSH-minor] Animals. Apoptosis / drug effects. Carcinoma, Ehrlich Tumor / drug therapy. Carcinoma, Ehrlich Tumor / metabolism. Carcinoma, Ehrlich Tumor / pathology. Delayed-Action Preparations. Drug Carriers. Female. In Vitro Techniques. Mice. Rabbits. Rats. Rats, Sprague-Dawley. Tissue Distribution

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18604659.001).
  • [ISSN] 1029-2330
  • [Journal-full-title] Journal of drug targeting
  • [ISO-abbreviation] J Drug Target
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Delayed-Action Preparations; 0 / Drug Carriers; 0 / Polyesters; 0 / hyaluronic acid-polyethyleneglycol-polycaprolactone copolymer; 80168379AG / Doxorubicin; 9004-61-9 / Hyaluronic Acid
  •  go-up   go-down


94. Alvero AB, Chen R, Fu HH, Montagna M, Schwartz PE, Rutherford T, Silasi DA, Steffensen KD, Waldstrom M, Visintin I, Mor G: Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle; 2009 Jan 1;8(1):158-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cancer stem cells (CSCs) provide a reservoir of cells that can self-renew, can maintain the tumor by generating differentiated cells [non-stem cells (non-CSCs)] which make up the bulk of the tumor and may be the primary source of recurrence.
  • These cells have a distinctive genetic profile that confers them with the capacity to recapitulate the original tumor, proliferate with chemotherapy, and promote recurrence.
  • CSC identified in EOC cells isolated form ascites and solid tumors are characterized by: CD44+, MyD88+, constitutive NFkappaB activity and cytokine and chemokine production, high capacity for repair, chemoresistance to conventional chemotherapies, resistance to TNFalpha-mediated apoptosis, capacity to form spheroids in suspension, and the ability to recapitulate in vivo the original tumor.
  • Chemotherapy eliminates the bulk of the tumor but it leaves a core of cancer cells with high capacity for repair and renewal.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Pharmacol. 2006 Dec;70(6):1946-55 [16940413.001]
  • [Cites] Eur J Cancer. 2006 Jun;42(9):1213-8 [16632344.001]
  • [Cites] Nature. 2006 May 25;441(7092):431-6 [16724054.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3859-68 [16585214.001]
  • [Cites] Cell. 2006 Mar 24;124(6):1111-5 [16564000.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10946-51 [16322242.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9328-37 [16230395.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3025-9 [15833827.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2005 May;288(5):G1055-65 [15826931.001]
  • [Cites] Nat Rev Cancer. 2005 Apr;5(4):275-84 [15803154.001]
  • [Cites] Nat Med. 1997 Jul;3(7):730-7 [9212098.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 4;102(1):99-104 [15615857.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1030-7 [17283135.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):259-73 [17349583.001]
  • [Cites] Cell Cycle. 2007 Feb 15;6(4):461-6 [17329969.001]
  • [Cites] Nat Med. 2007 Jul;13(7):851-6 [17572686.001]
  • [Cites] Oncogene. 2008 Jan 7;27(2):225-33 [18176604.001]
  • [Cites] RNA. 2008 Mar;14(3):577-83 [18218703.001]
  • [Cites] Cell Cycle. 2008 Jan 15;7(2):188-93 [18256530.001]
  • [Cites] Cell Cycle. 2008 Jan 15;7(2):242-9 [18256549.001]
  • [Cites] Cell Cycle. 2008 May 15;7(10):1360-70 [18418062.001]
  • [Cites] Cell Cycle. 2008 May 15;7(10):1371-8 [18421251.001]
  • [Cites] Cell Cycle. 2008 Jul 1;7(13):1931-5 [18604175.001]
  • [Cites] Oncogene. 2008 Aug 7;27(34):4712-23 [18408758.001]
  • [Cites] Cell Cycle. 2008 Dec;7(23):3622-4 [19029796.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Curr Opin Immunol. 2000 Apr;12(2):144-50 [10712944.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(11):2349-51 [10829060.001]
  • [Cites] J Clin Oncol. 2001 Apr 1;19(7):1901-5 [11283121.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):105-11 [11689955.001]
  • [Cites] Cancer Treat Res. 2002;107:99-118 [11775463.001]
  • [Cites] Nat Rev Cancer. 2002 Apr;2(4):301-10 [12001991.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] J Infect Dis. 2003 Jun 15;187 Suppl 2:S356-63 [12792852.001]
  • [Cites] Nat Rev Cancer. 2004 Jan;4(1):11-22 [14708024.001]
  • [Cites] Cell. 2004 Jul 23;118(2):229-41 [15260992.001]
  • [Cites] Cancer Cell. 2004 Sep;6(3):297-305 [15380520.001]
  • [Cites] Eur J Gynaecol Oncol. 1997;18(3):157-60 [9174825.001]
  • (PMID = 19158483.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA118678; United States / NCI NIH HHS / CA / R01 CA118678-03; United States / NCI NIH HHS / CA / 1R01 CA 118678-01A2; United States / NCI NIH HHS / CA / CA127913-02; United States / NCI NIH HHS / CA / CA118678-03; United States / NCI NIH HHS / CA / 1R01 CA 127913-01A2; United States / NCI NIH HHS / CA / R01 CA127913; United States / NCI NIH HHS / CA / R01 CA127913-03; United States / NCI NIH HHS / CA / R01 CA127913-02; United States / NCI NIH HHS / CA / CA127913-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Cytokines; 0 / Myeloid Differentiation Factor 88; 0 / NF-kappa B; 0 / Toll-Like Receptor 4
  • [Other-IDs] NLM/ NIHMS263794; NLM/ PMC3041590
  •  go-up   go-down


95. Silva LA, Nascimento KA, Maciel MC, Pinheiro MT, Sousa PR, Ferreira SC, Azevedo AP, Guerra RN, Nascimento FR: Sunflower seed oil-enriched product can inhibit Ehrlich solid tumor growth in mice. Chemotherapy; 2006;52(2):91-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sunflower seed oil-enriched product can inhibit Ehrlich solid tumor growth in mice.
  • BACKGROUND: Sunflower seed oil (SSO) effect on solid and ascitic forms of Ehrlich tumor was evaluated.
  • METHODS: Solid or ascitic Ehrlich tumor-bearing Swiss mice were treated daily, by subcutaneous route, with 200 microl of SSO.
  • The solid tumor-bearing footpad was measured every 3 days and ascitic tumor-bearing mice had their ascites collected and quantified.
  • RESULTS: Subcutaneous treatment with SSO inhibits the solid tumor growth and increases lymph node cell number in animals with solid tumor, but has no effect on animals with ascitic tumor.
  • CONCLUSIONS: SSO can delay the solid tumor growth, possibly due to better absorption of this treatment by draining lymph nodes.
  • [MeSH-major] Carcinoma, Ehrlich Tumor / drug therapy. Plant Oils / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel.
  • (PMID = 16462141.001).
  • [ISSN] 0009-3157
  • [Journal-full-title] Chemotherapy
  • [ISO-abbreviation] Chemotherapy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Plant Oils; 8001-21-6 / sunflower seed oil
  •  go-up   go-down


96. Sawamura A: [Surgical intervention in palliative care]. Nihon Rinsho; 2007 Jan;65(1):89-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In palliative care, surgical intervention is contra-indicated if there is intra-abdominal carcinomatosis as evidenced by diffuse intra-abdominal tumors, and massive ascites which re -accumulates rapidly after paracentesis.
  • Surgical intervention should be considered, if the following criteria are fulfilled even in palliative care. (1) The patient' s general condition is good, i.e. does not have widely disseminated disease and has been independent and active. (2) Previous laparotomy findings do not preclude the prospect of successful intervention. (3) An easily reversible cause seems likely, e.g. postoperative adhesions or a single discrete neoplastic obstruction. (4) The patient is willing to undergo surgery.

  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17233421.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 7
  •  go-up   go-down


97. Nikolin VP, Popova NA, Sebeleva TE, Strunkin DN, Rogachev VA, Semënov DV, Bogachev SS, Iakubov LA, Shurdov MA: [Effect of exogenous DNA on the growth of transplantable tumors]. Vopr Onkol; 2006;52(1):66-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of exogenous DNA on the growth of transplantable tumors].
  • Using transplantable Ehrlich ascites tumor, hepatoma HA-1 and Lewis carcinoma it was shown, that preparations of fragmented genomic DNA can more or less effectively inhibit such tumors as well as the growth of their metastases.
  • Such effects were produced by DNA preparations derived from tissues of mice, both syngeneic or allogeneic to tumor-bearer, as well as from human tissues.
  • [MeSH-major] Carcinoma, Ehrlich Tumor / drug therapy. Carcinoma, Lewis Lung / drug therapy. DNA / pharmacology. DNA Fragmentation. Liver Neoplasms, Experimental / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16715707.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 9007-49-2 / DNA
  •  go-up   go-down


98. Pissaia A Jr, Bernard D, Scatton O, Soubrane O, Conti F, Calmus Y: Significance of serum tumor markers carcinoembryonic antigen, CA 19-9, CA 125, and CA 15-3 in pre-orthotopic liver transplantation evaluation. Transplant Proc; 2009 Mar;41(2):682-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of serum tumor markers carcinoembryonic antigen, CA 19-9, CA 125, and CA 15-3 in pre-orthotopic liver transplantation evaluation.
  • Tumor markers are elevated in a variety of nonneoplastic clinical situations, including liver diseases.
  • Their sensitivity and specificity are lower for tumor screening in these cases.
  • In this study, we investigated the frequency and significance of elevated tumor markers in the pre-orthotopic liver transplantation (OLT) evaluation among patients with end-stage liver disease who did not develop tumors after a long follow-up post-OLT.
  • CA 125, CA 15-3, and CEA were associated with disease severity (Child-Pugh classification).
  • CA 125 was also elevated among patients with ascites, esophageal varices, or alcohol-related cirrhosis.
  • CA 15-3 levels were also increased among patients with elevated alkaline phosphatase, while elevated CEA was related to ascites, bilirubin, and prothrombin time (PT) levels, as well as alcohol-related cirrhosis.
  • There was no association between hepatocellular carcinoma and tumor markers.
  • In conclusion, CA 125, CA 19-9, CA 15-3, and CEA were frequently elevated among end-stage liver disease patients.
  • These elevations were not associated with tumor diseases in this population.
  • [MeSH-major] Biomarkers, Tumor / blood. CA-125 Antigen / blood. CA-19-9 Antigen / blood. Carcinoembryonic Antigen / blood. Liver Cirrhosis, Alcoholic / epidemiology. Liver Failure / epidemiology. Liver Transplantation / physiology. Mucin-1 / blood
  • [MeSH-minor] Ascites / blood. Ascites / epidemiology. Esophageal and Gastric Varices / blood. Esophageal and Gastric Varices / epidemiology. Humans. Retrospective Studies

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19328956.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen; 0 / Mucin-1
  •  go-up   go-down


99. Ussia A, Betsas G, Corona R, De Cicco C, Koninckx PR: Pathophysiology of cyclic hemorrhagic ascites and endometriosis. J Minim Invasive Gynecol; 2008 Nov-Dec;15(6):677-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathophysiology of cyclic hemorrhagic ascites and endometriosis.
  • Massive hemorrhagic ascites (4470 mL, range 1-10 L) in women with endometriosis is a rare condition occurring predominantly in black women.
  • Of the 43 case reports published, 42 are compatible with the hypothesis that the hemorrhagic ascites is predominantly a consequence of excessive ovarian transudation similar to a Meigs syndrome.
  • Indeed, bilateral ovariectomy cures the condition without recurrences, whereas after unilateral ovariectomy or cystectomy recurrence rate is more than 50%; during ovarian suppression by luteinizing hormone-releasing hormone agonist ascites disappears, but reappears after treatment.
  • Superficial pelvic endometriosis also contributes to the ascites because after superficial endometriosis destruction the recurrence rate is only 4 in 14.
  • Based on these data, it is suggested, to scrutinize the ovaries for tumors given the analogy with Meigs syndrome.
  • [MeSH-major] Ascites / physiopathology. Endometriosis / physiopathology. Hemorrhage / epidemiology. Menstrual Cycle / physiology

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Bleeding.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18971129.001).
  • [ISSN] 1553-4650
  • [Journal-full-title] Journal of minimally invasive gynecology
  • [ISO-abbreviation] J Minim Invasive Gynecol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 51
  •  go-up   go-down


100. Suzuki R, Takizawa T, Negishi Y, Utoguchi N, Sawamura K, Tanaka K, Namai E, Oda Y, Matsumura Y, Maruyama K: Tumor specific ultrasound enhanced gene transfer in vivo with novel liposomal bubbles. J Control Release; 2008 Jan 22;125(2):137-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor specific ultrasound enhanced gene transfer in vivo with novel liposomal bubbles.
  • In this study, Bubble liposomes were compared with cationic lipid (CL)-DNA complexes as potential gene delivery carriers into tumor in vivo.
  • In addition, Bubble liposomes could introduce the luciferase gene more effectively than CL-DNA complexes into mouse ascites tumor cells and solid tumor tissue.
  • We conclude that the combination of Bubble liposomes and ultrasound is a minimally-invasive and tumor specific gene transfer method in vivo.
  • [MeSH-minor] Animals. COS Cells. Cell Line, Tumor. Cercopithecus aethiops. Erythrocytes / drug effects. Gene Targeting / methods. Hemolysis / drug effects. Male. Mice

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • Hazardous Substances Data Bank. Octafluoropropane .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18035442.001).
  • [ISSN] 1873-4995
  • [Journal-full-title] Journal of controlled release : official journal of the Controlled Release Society
  • [ISO-abbreviation] J Control Release
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Fluorocarbons; 0 / Liposomes; 9007-49-2 / DNA; CK0N3WH0SR / perflutren
  •  go-up   go-down






Advertisement